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1. INTRODUCTION 
 
The human immunodeficiency virus (HIV) is one of the major plague in the world for new 
cases of infection, number of people infected and deaths.  
In 2012, 2.3 million of new HIV infections (1.9 million–2.7 million) and 35.3 million of 
HIV-positive people have been reported all over the world [1]. 
Since its isolation, in the 1983, HIV has represented a social, economic and  sanitary issue. 
Despite the massive scale up of antiretroviral therapy (ART) has dramatically prolong the 
life of HIV-infected individuals and the number of new infections is decreasing, for every 
10 people starting antiretroviral therapy 16 people are newly infected [2]. Today, a 
winning HIV/AIDS strategy does not exist, and the escalating cost for treatment will 
become increasingly difficult for undeveloped countries to meet. Strategies for either 
eradicating the virus from infected individuals or boosting their immune response so that 
antiviral drugs can be discontinued are urgently needed. 
The most devastating damages caused by HIV infection are observed at level of cellular 
immunity and include the depletion of CD4
+
 T cells and important dysfunctions of both 
CD8
+
 and CD4
+
 T cells as impairment of functionality [3, 4], exhaustion [5], increased T 
cell proliferation [6], susceptibility to apoptosis [7, 8] and expansion of memory T cells [9-
11]. This status of chronic immune activation and immune senescence involves the whole 
T cell compartment, including uninfected and non-HIV specific T cells [12], is also present 
during ART and contributes to the appearance of AIDS-defining and non-defining diseases 
[13]. Different mechanisms contribute to these phenomena including CD4
+
 T cells loss, 
viral replication and effects of HIV proteins such as gp120, Nef and Tat [6, 12]. However, 
how HIV can modulate the CD8
+
 and CD4
+
 T cells responses is not completely clear.  
 
1.1 IMMUNE SYSTEM 
 
The immune system is a rapid, specific and powerful mechanism of defense against 
viruses, bacteria and other potential dangerous microorganisms. 
It is divided in two major sectors, the innate immunity and the adaptive immunity (Figure 
1.1).  
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Figure 1.1. The innate and the adaptive immunity. Adapted by [14] 
 
 
1.1.1 Innate immunity 
 
The innate immunity system consists of multiple distinct subsystems that perform different 
functions in host defense. 
The first defense consists in preformed soluble molecules like complement and cytokines, 
present in blood, extracellular fluid, and epithelial secretions that can kill or inhibit the 
proliferation of some classes of pathogens. The second defense is mediated by cells like 
Natural Killers (NKs), eosinophils, basophils, and mast cells specialized in the recognition 
of specific microbial structures and molecules such as PAMPs (pathogen associated 
molecular patterns) and DAMPs (damage associated molecular patterns) [14, 15], 
identified by cellular pattern recognition receptors (PRRs). 
PRRs recognition of microbial structures causes a cascade of intracellular events that leads 
to pro-inflammatory cytokines and chemokines release, and to phagocytosis mediated by 
macrophages and dentritic cells (DC). On the whole these responses cooperate with co-
stimulatory molecules, soluble or expressed on the cells surface, to activate adaptive 
immune cells. 
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1.1.2 Adaptive immunity 
 
Adaptive immunity is carried out by cells called lymphocytes which act through two 
classes of responses: antibody response and cell-mediated immune response. 
The first is mediated by B lymphocytes (B cells) which are responsible of the release of 
antibodies such as IgG, IgM, IgA, IgE. The latter is triggered by T lymphocytes (T cells), 
which are divided in two subpopulations: CD4
+
 T cells, also known as T helper 
lymphocytes (Th), and CD8
+
 T cells, also known as cytotoxic T lymphocytes (CTLs). 
 
1.1.3 CD4
+
 T cells 
 
CD4
+
 T cells are the main orchestrators of immune responses to infections. This subset of 
T cells is extremely important for the optimal activation and development of memory 
CD8
+
 T cells [16], for the secretory activity of B and NK cells and for the antigen 
metabolism of professional antigen presenting cells (APC). 
CD4
+
 T helper subsets include Th1, Th2, Th17  and Treg cells [15, 17] (Figure 1.2 and 
Table 1.1). There are evidences that each of these subsets is involved in the defense against 
specific microorganisms.  
 
Figure 1.2. CD4
+
 T cells generation. Adapted by [18] 
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Th1 cells mediate immune responses against intracellular pathogens [19]. Concerted with 
antigen recognition, interleukin-12 (IL-12) is the cytokine that drives naïve CD4
+ 
T cells 
into Th1 subset type. IL-12Rβ1 is constitutively expressed on naïve CD4+ T cells and its 
expression is increased in Th1 cells. The most important cytokine products of Th1 cells are  
interferon-γ (IFNγ), lymphotoxin α (LTα), and IL-2. IFNγ is important to activate 
macrophages and CD8
+
 T cells, and increases antigen processing and presentation to T 
cells [20]. IL-2 production is critical for CD4
+
 and CD8
+
 T-cell memory maintenance since 
it promotes cell survival, inducing the expression of the anti-apoptotic protein Bcl-2 [19, 
21]. IL-2 can also stimulate the activation and proliferation of CD8
+
 T cells and enhances 
the expression of co-stimulatory molecules on APCs surface and the production of other 
cytokines in favor of CD8
+
 T cells. Moreover, IL-2 induces the release of other cytokines 
like IL-4, important for the development of other Th subsets and stimulates the 
proliferation of NK and B cells. LTα activates neutrophils and lymphoid organogenesis. 
 
Th2 cells mediate host defense against extracellular parasites including helminthes [22-
24]. The induction of Th2 subset is regulated by IL-4 that acts with a mechanism of 
feedback to produce itself and IL-5. Those cytokines produced by Th2 cells, promote the 
production of IgE and the differentiation and activation of eosinophils [20]. Th2 cells also 
support B lymphocytes stimulating the production of large amount of IgM. IL-4 
antagonizes the macrophage-activating actions of IFNγ and, in association with IL-5, can 
inhibit acute and chronic inflammation, limiting consequences due to persistent Th1 
immune responses. 
 
Th17 cells mediate immune responses against extracellular bacteria and fungi [25]. Their 
cytokine products are IL-17, IL-21, and IL-22. IL-17 recruits and activates neutrophils 
during immune responses [26], while IL-21 is a stimulatory factor for Th17 differentiation 
and serves as positive feedback, as does IL-2 for Th1 and IL-4 for Th2 cells. In addition, 
IL-21 acts on CD8
+
 T cells, B cells, NK cells, and dendritic cells [27]. IL-22 mediates host 
defense against bacterial pathogens, and these functions may largely depend upon IL-23 
stimulation of innate cells. 
 
 
Treg cells play a critical role in maintaining self-tolerance as well as in regulating immune 
responses [28]. Treg cells exert their suppressive functions through several mechanisms, 
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some of which require cell-to-cell contact or the production of cytokines, including TGF-β 
and IL-10. High levels of CD25 and IL-2Rα expression on Treg cells suggest the 
importance of IL-2 to regulate proliferation and induction of Treg suppressor activity.  
 
T helper lineage 
Cytokines 
production 
Inductive 
cytokines 
Role 
Th1 IFNγ  
IL-2 
IL-12 
IL-2 
IFNγ 
Mediate immune responses against 
intracellular pathogens: NK, 
macrophages, CTLs activation and IFNγ 
secretion 
Th2 IL-4 
IL-5 
IL-6 
IL-4 
IL-2 
Mediate defense against extracellular 
parasites; Promotion of IgE and 
eosinophil/basophil/mast cell-mediated 
immune reaction 
Th17 IL-17 
IL-21  
IL-22 
IL-6 
TGF-β 
Mediate immune responses against 
extracellular bacteria and fungi; Release 
of proinflammatory cytokines, activation 
of T cells, NK and neutrophils 
Treg TGF-β 
IL-10 
TGF-β 
IL-10 
IL-2 
Regulation and suppression of immune 
response 
Table 1.1. The CD4
+
 T cells subsets 
 
 
 
1.1.4 CD8
+
 T cells 
 
CD8
+
 T cells are critical to protect the organism against intracellular pathogens and tumor 
cells. In contrast to CD4
+
 T cells, CD8
+
 T cells are the direct executioners of pathogen-
infected cells.  
During the immune response to viruses and intracellular microbes, naïve CD8
+
 T cells are 
activated in cytotoxic T lymphocytes (CTL) to undergo a massive clonal expansion, with 
acquisition of new effector functions. 
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After antigen recognition, CTLs proliferate and kill the cellular target mainly with three 
mechanisms: 
- Exocytosis of granules containing perforin that polymerize on target cell membrane 
causing osmotic cell lysis. 
- Secretion of granzymes (serine proteases) that induce apoptosis in target cells [29]. 
- Expression of Fas ligand (FasL) that induces apoptosis by a specific and direct interaction 
with Fas molecules present on target cells [30]. Target killing by CTLs is antigen specific 
and contact dependent. 
 
1.2 CD4
+
 AND CD8
+
 T CELLS ACTIVATION  
 
T lymphocytes mount specific responses against antigens (Ags) which are peptides 
generated by the cellular proteolytic system (“antigen processing”) and are presented 
through MHC molecules to the TCR. MHC class I and the MHC class II molecules, also 
known as Human Leukocyte Antigen (HLA), are controlled by genes located on 
chromosome 6, that encodes cell surface molecules specialized to present antigenic 
peptides to T cells. All MHC-I molecules consist of two polypeptide chains, a heavy chain 
α and a monomorphic light chain β2-microglobulin (β2m).  
The two chains are linked non-covalently via interaction of β2m and the α3 domain. Like 
MHC class I molecules, MHC-II molecules are also heterodimers, but in this case consist 
of two homologus peptides, an α and β chains, both of which are encoded in the MHC 
(Figure 1.3).  
 
Figure 1.3. MHC classes I and II molecule structure 
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The MHC-I system draws its spectrum of peptides from proteins in the cytosol of all 
nucleated cells. In contrast to MHC-I, MHC-II molecules are expressed on a more limited 
set of cells called APC cells such as somatic cells, B cells, macrophages and dendritic 
cells. Thereby, MHC molecules are a molecular reflection of the health of cells that 
synthesize them (for MHC-I molecules) or of the local environment in which cells reside 
(for MHC-II molecules).  
MHC-I and MHC-II molecules also show a different interaction with T cells. In particular, 
the nonpolymorphic α3 domain of MHC-I binds the CD8 co-receptor of T cells while the 
membrane proximal domains of MHC-II interacts exclusively with the CD4
 
molecule. 
CD8 and CD4 molecules serve as co-receptors on the surface of T lymphocytes, providing 
both adhesion and specific activation signals that modulate T cells. Epitope associated to 
the MHC molecules migrate to the cell surface to be recognized by the specific TCR.  
The TCR is a disulfide-linked membrane-anchored heterodimer normally consisting of the 
highly variable α and β chains expressed as part of complex with the invariant CD3 chain 
molecules [31] (Figure 1.4).  
 
Figure 1.4. T cell Receptor 
 
The generation of TCR diversity is based on somatic recombination of the DNA encoded 
segment in individual T cells. 
The combinatorial rearrangement of multiple gene segments, the error-prone process of 
joining these different fragments, and the various combinations of α with β chains or the 
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less represented γ with δ chains lead to big TCR diversity and, thereby, enables receptors 
to respond to a broad spectrum of antigens that pathogens show.  
It is known that activation of T cells requires multiple signals: signal 1, antigen-specific 
delivered via TCR/MHC interaction, signal 2, delivered by co-stimulatory molecules 
(including IL-2), and signal 3, delivered by pro-inflammatory cytokines and chemokines 
[32].  
Several co-stimulatory receptors are exposed on T cells surface; among them, CD28 and 
CTLA-4 co-stimulatory molecules bind B7 receptor on APCs surface. CTLA-4-mediated 
inhibitory signals dominate when T cells encounter antigen on APCs expressing low levels 
of B7, while CD28 activating signals dominate when antigen is presented by APCs with 
high B7 levels [33-35]. CD28 co-stimulation is responsible for the activation of c-Jun 
kinase and PI3K/AKT/mTOR axis, thus contributing to anti-apoptotic effects due to the 
up-regulation of Bcl-2. Physiologically, a balance among MAP kinase family enzymes, in 
particular between ERK and c-Jun, is important for T cell survival and, while ERK is 
activated through TCR stimulation, c-Jun depends mostly by CD28 signalling [36]. 
In addition, CD3 seems to be responsible for signal transduction following the antigen 
recognition events. This idea was suggested by the observation that antibodies directed 
against CD3 proteins generate the same T cell activation events as stimulation of T cells 
with peptide antigen plus MHC [37, 38]. 
Co-stimulators are required for the full maturation of responses in T cells. Furthermore, the 
combination of these signals induces cytokines secretion, clonal expansion and 
differentiation of precursor CD4
+
 and CD8
+
 T cells into effector (Figure 1.5).  
Figure 1.5. Immune CD8
+ 
(a) and CD4
+ 
(b) synapsis 
Introduction 
15 
 
In concert with antigen recognition, the cytokine environment modulates the polarization 
of T-cell homeostasis. In particular, IFNγ, IL-2, IL-7, IL-4, IL-9, IL-12 and IL-15 supply 
survival and expansion of CD4
+
 and CD8
+
 T cells.   
The T cell activation provided by TCR, co-stimulatory molecules and cytokines determine 
the change of transcription factors (TFs) expression that act as master regulators by 
controlling the expression of a panel of genes and conferring a specific phenotype. A large 
number of TFs participate in initial T cell activation, such as nuclear factor of activated T 
cells (NFAT), activating protein-1 (AP-l), and nuclear factor-kappaB (NF-kB), that interact 
with transcriptional partners determining the activation of T cells.  
NFAT is required for the expression of IL-2, IL-4, TNF, and other cytokine genes. 
Interestingly, productive T cells activation not only requires prolonged nuclear NFAT, but 
also depends on physical interactions between NFAT and AP-1 on composite promoter 
elements. Activation of AP-1 typically involves synthesis of Fos protein and 
phosphorylation of c-Jun protein. 
NF-kB is a transcription factor that is activated in response to TCR signals and is essential 
for cytokine synthesis. NF-kB fulfills a central role in the cellular stress response and in 
inflammation by controlling the expression of a network of inducers and effectors that 
define responses to pathogens and other classes of danger signals [39]. 
Following NFAT, AP-1 and NF-kB dependent T cell activation, a subsequent phase of 
clonal expansion ensues.  
 
1.2.1 CD4
+
 and CD8
+
 T cells programming 
 
CD4
+
 Th1/Th2 balance is regulated by T-bet and GATA3, both induced by TCR 
stimulation and by several cytokines. T-bet enhances responsiveness to IL-12 favoring  IL-
12Rβ2 expression and is regulate by or regulate IFNγ production, thus supporting a Th1 
phenotype; while GATA3 is the TF responsible for the acquisition of a Th2 lineage 
promoting IL-4 secretion [40, 41]. T-bet and GATA3 are regulated by mTOR kinase 
through activation of the PI3K-Akt pathway [42]. STAT proteins also regulate the 
expression of many genes required for the differentiation of various CD4
+
 T helper cell 
lineages.  
Therefore, STAT1 and STAT5 contribute to Th1 differentiation by enhancing T-bet and 
IFNγ expression, respectively, while STAT6 mediates IL-4 production and Th2 
differentiation [41, 43]. 
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During CD8
+
 T cell-mediated immune response, Eomesdermin (Eomes), another T-box 
transcription factor like T-bet, is essential for the development of effector  and memory 
phenotype.  
Eomes is crucial in first phase of CD8
+
 effector development and along with T-bet it 
regulates CD8
+
 cytotoxic functions [44]. Otherwise, Eomes and T-bet expression are 
inversely related in central memory (TCM) cells [45]; while T-bet decreases in the 
contraction phase, Eomes expression is necessary. The level of inflammation and the 
availability of certain cytokines (e.g. IL-12) influence the levels of T-bet and Eomes 
available to the effector cell and that this in turn influences which cells will remain CD8
+
 
effector T cells and which will transition to the memory CD8
+
 T cell pool [46]. 
Other two transcription factors crucial for the activation and the development of CD4
+
 and 
CD8
+
 T cells are Blimp-1 and Bcl-6, that are reciprocally antagonist. Blimp-1 is a 
transcriptional factor encoded by Prdm1 and correlated to effector and memory functions 
of both CD8
+
 and CD4
+
 T cells. Blimp-1 in CD8
+
 T cells negatively regulates Bcl-6 and, 
as in CD4
+
 T cells, it is activated by IL-2 driving CD8
+
 T cells to CTLs differentiation. 
Bcl6 is a transcriptional repressor of granzyme B and it is involved in CD4
+
 and CD8
+
 
memory T cells formation [47]. Although many aspects of Blimp-1 and Bcl-6 regulation in 
CD4
+
 T cells are still unclear, some studies suggest a key role of Bcl-6 in CD4
+
 T cells 
survival and proliferation as well as Tfh formation. In addition, it has been demonstrated 
the significant influence of Blimp-1 in terminal effector cells differentiation and in Th1 
maturation where it interacts with T-bet [48] (Table 1.2 and Figure 1.6). 
 
 Activated CD8
+
 
T cells 
Activated CD4
+
 T cells 
Th1 Th2 Th17 Treg 
TFs expression Blimp-1 
T-bet  
Eomes 
T-bet 
Blimp-1 
STAT1 
STAT5 
Gata3 
STAT6 
Bcl-6 
RORγt 
Foxp3 
 
Table 1.2. Transcription factor expressing in activated T lymphocytes   
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Figure 1.6. Transcriptional signaling after activation in CD4
+
 (a) and CD8
+
 (b) T cells. Adapted by [49] 
 
 
Intensity of stimuli through TCR-MHC signaling, cytokines production and presence of 
different subsets of immune cells can deeply modulate transcription factors programming 
in both CD4
+
 and CD8
+
 T cells, driving the immune response to different fates. 
The modulation of T cell responses to antigen and the improvement of activation are goals 
extremely important for the development of new therapies and vaccines against tumors and 
pathogens. 
 
1.2.2 Memory CD4
+
 and CD8
+ 
T cells 
 
During a response to infection, there are three characteristic phases: a period of initial cell 
activation and expansion, a contraction or death phase, and the establishment and 
maintenance of immunological memory (Figure 1.7).  
 
Figure 1.7. T cells differentiation and fate. Adapted by [18] 
Introduction 
18 
 
 
There are two competing models of memory T cell development: linear and not-linear 
divergent differentiation. In the linear model, activated naïve T cells develop initially into 
effector cells and, a small fraction of these cells, survives at contraction phase and becomes 
memory cells. In the not-linear divergent model, a fraction of activated naïve T cells 
differentiates directly into memory cells. Both these theories are supported by different 
reports however, recently some studies indicate the linear model as the most consistent [50, 
51]. 
Memory cells are divided  into two different subpopulations: “central memory” (TCM) and 
“effector memory” (TEM) (Table 1.2). 
Table 1.3. Memory phenotype and secretion capacity 
 
TCM reside mostly in lymph nodes and are responsible for the clonal expansion after re-
exposure to antigen, while TEM are disseminated within peripheral tissues where they 
display immediate effector functions. The role and the homing capacity of memory cells is 
determined by their phenotype. For instance, the expression of some cellular markers like 
CCR7 and CD62L on memory cells surface regulate their susceptibility to antigen and 
consequently cells proliferation and cytokines release. Cells proliferation and cytokines 
production represent the two main aspects of this population. Indeed, while TCM are 
extremely proliferative but have a low cytokine secretion capacity after antigen 
recognition, TEM are not so efficient in proliferation but display high secretory potential.  
 
During acute viral infection, antigen-driven differentiation of naive CD8
+
 T cells leads to 
the expression of cytolytic molecules and cytokines that facilitate the control of infections. 
 Phenotype Molecules secreted 
Central memory (TCM) 
CCR7 High 
CD62L  High  
CD44 
IL-7 Receptor (CD127) 
IL-15 Receptor (CD122) 
CXCR5 
IFNγ low 
IL-2 high 
IL-4 low 
CD40 ligand 
IL-17A 
Effector memory (TEM) 
CD62L  Low 
CD44 
IL-7 Receptor (CD127) 
IL-15 Receptor (CD122) 
CD45RA 
IFNγ 
IL-4 
IL-5 
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After the expansion and contraction phases, during which the infection is cleared, some  
antigen-specific CD8
+
 T cells survive and gain the capacity of self-renewal in lymphoid 
and non-lymphoid tissues, and a heightened ability to recall effector functions relative to 
their naïve precursors. Molecular studies of CD8
+
 T cells differentiation during acute viral 
infection have demonstrated that at the effector stage, memory precursor cells destinated to 
survive into the memory phase, can be identified by some transcriptional factors such as 
Eomes, Blimp-1 and cellular marker like CD127 (IL-7 receptor), CD62L (homing in 
lymphoid organs) and CD122 (IL-15 receptor) [52, 53]. The long term maintenance of 
memory CD8
+
 T cells does not require the antigen stimulation, but it is dependent on IL-7 
and IL-15 signalling that mediates homeostasis and survival, up-regulating anti-apoptotic 
molecules such as Bcl-2 [54].  TCM CD8
+
 T cells seem to originate from a subset of 
effector cells called MPEC, memory precursor effector cells, in contrast to SLEC, short 
lived effector cells. The balance of MPEC/SLEC among a population of effectors depend 
by the overall amount and duration of activation signals, thus the first 48-96 hours of 
stimulation determine the fate of the future memory population. In particular, the 
development of TCM cells is dictated by a short and reduced antigenic stimulation [55, 56]. 
 
Naïve CD4 T cells must usually interact with mature antigen-loaded dendritic cells to be 
successfully activated. This interaction takes place in the T-cell areas of secondary 
lymphoid organs, locations that have evolved to facilitate contact between antigen-specific 
T cells and DCs. CD4
+
 T cells require prolonged and high TCR signaling stimulation in 
order to differentiate into effectors and subsequently form the memory pool [57]. Memory 
CD4
+
 T cells express much lower levels of CD122, that correlates with a lower 
dependence on IL-15 compared to CD8
+
 T cells. However, IL-7 appears to be the main 
survival cytokine for CD4
+
 memory cells, as cells cannot survive in its absence. Moreover, 
memory CD4
+
 T cells life tends to be shorter than that of memory CD8+ T cells [58]. 
Memory CD4
+
 T cells are important during the “clinical latency” phase of HIV which is 
accompanied by the establishment of cellular reservoirs, resting memory CD4
+
 T cells that 
host the integrated virus with low expression of viral antigens, not to be eliminated by the 
adaptive immune system [59]. In the case of chronic or latent infections, and particularly 
during the HIV infection, the persistence of the pathogen misleads the physiological 
development of the cellular response, affecting the functionality of memory cells, that can 
exhibit poor recall proliferation, exhausted phenotype, loss of effector functions and a 
skewed composition of T cell memory subpopulations [60]. 
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1.3 THE HIV INFECTION  
 
In 1981 appeared, in Unites States, a new disease, characterized by a deficiency in the 
immune system [61] which consists in a marked reduction in CD4
+
 cell numbers and 
enhanced B-cell proliferation and hypergammaglobulinemia. After two years of research, 
this disease known as acquired immune deficiency syndrome (AIDS), was connected to a 
new human retrovirus named HIV [62]. The AIDS viruses, HIV-1 and HIV-2, consist of 
different virus groups and a lot of different clades subtype for every virus group. Based on 
their genetic differences, four groups of HIV-1 (M, N, O, P) have been identified and 
inside these groups it is possible to distinguish 9 subpopulations or clades (A, B, C, D, F, 
G, H, J, K). The four groups of HIV-1 isolated differ from each other by the chemokine 
receptor they use for cell entry. HIV viruses that use to enter cells the chemokine receptor 
4 (CXCR4) are termed X4, the ones that use chemokine  receptor 5 (CCR5) are termed R5, 
and the others that use both CXCR4 and CCR5 are termed R5X4 [63].  
HIV viral particles have a diameter of about 100 nm and are built in a concentric structure 
consisting in an envelope, a matrix and a capsid. The capsid contains the genome, 
composed by two identical copies of single stranded RNA that codifies for three major 
genes (gag, pol, and env) and six accessory genes (tat, rev, nef, vpr, vif, and vpu) (Figure 
1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. The HIV virus and genome 
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Structural proteins composing the viral particles are encoded by env and gag, while the pol 
gene encodes for enzymes crucial for viral replication (reverse transcriptase, integrase, 
protease). The regulatory proteins deriving from accessory genes exert functions important 
for viral infectivity and replication, as well as for the immune system impairment. 
HIV-1 is one of the most polymorphic viruses known and exists as a swarm of genetically 
related variants. The polymorphic nature of HIV-1 can be directly attributed to its error 
prone reverse transcriptase and complexity of its cDNA formation. Together with other 
host factors, the evolution of the viral genome underlies all of the changes in the biological 
characteristics of HIV-1 including cytopathic ability, immune evasion, co-receptor usage 
and tropism. 
CD8
+
 T cells seems to play a key role in the control of HIV infection, as the detection of 
HIV-specific CTLs coincides with a viral load decline [64], and some HLA class I alleles 
are associated with the control of the infection [65]. HIV mutates the dominant epitopes to 
avoid cellular immunity, and protective CTL responses put pressure on mutations that 
result in a loss of replication competence. This dynamic process also leads to continues 
changes in the virus and, thus, to the development of genetically diverse viruses in the 
single individual [66]. This great variability makes extremely difficult the search for a 
vaccine that can induce protective antibodies and both innate and adaptive cellular immune 
anti-HIV responses capable of controlling the disease. Up to now, the development of 
vaccines against HIV has been explored, in addition to prevent HIV acquisition, also to 
control viral replication and disease progression in HIV-infected individuals, with the aim 
to discover therapeutic vaccines that may substitute ART.  
Vaccine candidates able to induce cellular response were developed but the results were 
not promising, and the trial was stopped for an increased risk of HIV acquisition in 
vaccines [67], due to some pre-existent immunity to the viral vector used, and to an 
inappropriate bias of CTL responses towards less conserved epitopes. 
However, nowadays no candidates have been shown to be highly immunogenic and, at the 
same time, confer protection from viral rebound after ART interruption [68, 69]. Thus, the 
research on preventive and therapeutic vaccines against HIV is still ongoing. 
One of the most important barriers to the elimination of HIV is its persistence in cellular 
reservoirs [70], that consist in latently infected central memory and transitional memory 
CD4
+
 T cells [71]. Their homeostatic proliferation, low proliferation rates and long term 
maintenance sustained by IL7 and IL15 make them a very stable viral reservoirs [71]. 
Latently infected CD4
+
 T cells may persist in the body for many years and are supposed to 
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derive from infected activated CD4
+
 T cells that switch to a resting memory phenotype and 
reduce the transcription factors required for HIV replication. 
 
1.3.1 EFFECTS OF HIV ON CD4
+ 
AND CD8
+
 T CELLS 
 
As mentioned above, the most devastating damages caused by HIV infection are observed 
at level of cellular immunity. 
Depletion of CD4
+
 T cells is a primary reason for the opportunistic infections and cancers 
associated with HIV infection. Several factors can be involved in this CD4
+
 T cells loss: 
effects on permeability of cell membrane due to virus replication, induction of apoptosis 
via immune activation or viral replication, direct cytopathic effects of HIV, anti-CD4
+
 
autoantibodies, anti-CD4
+
 T cells cytotoxic activity [72, 73] and destruction of bone 
marrow [74].  CD4
+
 T cells depletion can be also increased by cytokines, like TNF-α and 
several HIV protein such as Nef, gp120, Vpr and Tat may also affect CD4
+
 T cells 
viability. Moreover, autophagy has been noted as a possible cause of bystander CD4
+
 T 
cells death following HIV infection [73].  
CD8
+
 T cells play a pivotal role in the suppression of viral replication and in the clearance 
of virally infected cells during HIV infection. Besides, CTLs from HIV-infected patients 
appear to degenerate into a functionally impaired state, irrespective to ART treatment [75]. 
HIV down-regulates surface MHC-I expression from infected cells, by altering the pattern 
of cytokine production, T cell signaling and engagement of cellular receptors [76] and  the 
down-regulation of CD3 and CD28 has been associated with defects in TCR stimulation. 
Indeed, the HIV accessory genes Vpu and Tat play an important role in MHC-I down-
regulation [77]. 
Dysfunctionality of T lymphocytes in HIV-positive patients has been linked to the deep 
modification of their transcriptional profile [78, 79]. In particular, it has been shown that 
CD8
+
 T cells from HIV-positive patients display an effector phenotype and a simultaneous 
increased expression of two T-box transcription factors, T-bet and Eomes [79]. 
High HIV virus levels correlate with higher level of Eomes in CD8
+
 T cells memory. Also 
T-bet may play a role in increasing the cytotoxic potential observed in HIV-specific CD8
+
 
T cells. Besides, it has been found that a high level of T-bet correlates with a better control 
of HIV virus replication. T-bet expression is strongly correlated with perforin and 
granzyme B production and may influence the effector status of HIV-specific CD8
+
 T cells 
[80, 81]. 
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HIV also enhances the secretion of the anti-inflammatory cytokine transforming growth 
factor (TGF-β) by CD8+ T cells, thus inhibiting the IFNγ response to HIV antigens. In 
CD8
+
 T cells from HIV-positive patients, activation of the mitogen activated protein kinase 
(MAPK) results in the activation of transcription factor cascade that regulates such cellular 
processes as cell cycle, stress response, apoptosis, differentiation and proliferation [76] 
(Figure 1.9).  
Figure 1.9. HIV effects on CD8+ T cells. Adapted by [76] 
 
 
1.4 HIV-1 TAT PROTEIN 
 
HIV-Tat is a small protein whose length varies between 80 and 103 residues (14 KDa) 
depending on the different position of transcriptional stop codons in the second coding 
exon [82]. The predominant and most common form is 101 residues long (Figure 1.10). 
 
Figure 1.10. HIV-1 Tat sequence conservation. Letter size is proportional to residue conservation [83] 
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Tat is required for HIV-1 transcription and is therefore able to reach the nucleus. During 
the earlier (Tat-independent) initiation phase of HIV replication, a short RNA, trans-
activation response element (TAR), is produced from the HIV-1 long terminal repeat 
(LTR).  
In the elongation phase, Tat, cyclin T1 and CDK9 form a ternary complex that binds TAR 
and then induces the phosphorylation of RNA polymerase II, enabling the production of 
full-length HIV-1 transcripts and their release. 
When Tat is present, 99% of the transcripts are transcribed to their full length. However, in 
the absence of Tat, 87% of the initiated transcripts terminate prematurely at positions +55 
to +59 [84].  
Besides its involvement in viral replication, Tat is implicated in HIV spread. Indeed, its 
expression prior viral integration, can strongly increase the number of the HIV-1 co-
receptors CXCR4 and CCR5 at the surface of CD4
+
 T cells, favoring viral infection [85]. 
After HIV infection, Tat is early produced and secreted by infected T cells and in the 
absence of cell lysis and can alter functions of both infected and uninfected T cells. Tat 
reaches the cytosol using a pathway that relies on endocytosis, low pH-driven membrane 
insertion and Hsp90-catalysed translocation. Intriguingly, the Tat concentration detected in 
supernatant during in vitro experiments of infection reaches the same levels observed in 
sera of HIV-1-infected individuals. 
After the release in sera, Tat can bind heparan sulphate proteoglycans (HSPGs) [86] and 
the integrin receptors α5β1 and αVβ3 through its Arg-Gly-Asp (RGD) motif (residues 78–
80) and enters in uninfected cells [87-89]. 
Six distinct functional domains have been characterized in the Tat protein: 
1. N-terminal (amino acids 1–21), 
2. Cysteine-rich (amino acids 22–37) 
3. Core (amino acids 38–48) 
4. Basic (amino acids 49–57) 
5. Glutamine rich region (58-72) 
6. C-terminal (amino acids 73–86/101) 
The N-terminal domain binds bivalent ions able to mediate interactions among Tat 
monomers; the cysteine-rich and core domains are highly conserved and are necessary for 
LTR transactivation (the absence cause the loss of Tat transactivation activity); the basic 
domain consists of a stretch of basic amino acids necessary for nuclear localization, 
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binding to TAR-RNA and to with heparan sulfate; the C-terminal domain of Tat is encoded 
by the second exon and contains an RGD motif typical of extracellular matrix proteins, 
which mediates the binding with integrins [90, 91].  
Several studies have reported that HIV-1 Tat protein activates CD4
+
 T cells and increases 
pro-inflammatory cytokine production in both HIV-infected and uninfected cells [92].  
Tat protein, possesses several immunomodulatory features making it an attractive molecule 
to be exploited for vaccination strategies and therapeutic interventions aimed at modulating 
antigen-specific immune responses in different types of human diseases [92]. In particular, 
the biologically active clade B Tat protein targets very actively immature dendritic cells, 
induces their maturation and polarizes the immune response to the Th1 pattern through 
transcriptional activation of TNFα gene expression, leading to a more efficient presentation 
of both allogeneic and heterologous antigens [93]. In addition, Tat possesses intrinsic 
adjuvanticity attributed to its capacity to dimerize [169], increases the number of Treg cells 
[67] and induces protective immunity against Leishmania major [94]. 
Moreover, it has been demonstrated that anti-Tat immunity is important to control the 
disease and to restore immune functions [82, 95], suggesting that Tat may contribute to 
immune activation. 
 
1.4.1 Effects of HIV-Tat protein on CD4
+
, CD8
+
 T cells and APCs 
 
As mentioned before, Tat can be released by infected cells and be internalized by other 
cells through binding heparan sulfate [86], integrin receptors [96] and via endocytosis [97]. 
Tat displays several effects on T cells, including activation, proliferation [92, 98], 
apoptosis [98, 99] and also favors the expression of chemokines and cytokines [100, 101].  
Tat activates CD4
+
 T cells after anti-CD3/CD28 stimulation, in a mechanism dependent by 
CD28 co-stimulation that enhances IL-2 secretion [92] and may result in an increased 
susceptibility to HIV-1 infection [102]. Moreover, Tat inhibits the NAD-dependent 
deacetylase sirtuin-1 (SIRT1) activity [103] potentiating NF-κB transcriptional activity and 
unveils a molecular mechanism by which hyperactivation of immune cells is promoted 
during HIV infection. In addition, it has been shown that Tat induces the release of other 
pro-inflammatory cytokines involved in T cells activation and differentiation, such as IL-8, 
IL-12 and TNFα [104, 105]. Along with IFNγ secretion induced by CD4+ T cells, it has 
been observed a strong up-regulation of T-bet expression which is mainly implicated in 
generating Th1 type of immune response [105].  
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CD4
+
 and CD8
+
 T cells hyper activation is a feature of chronic immune activation, and 
Tat-mediated enhanced proliferation of CD4
+
 T lymphocytes has been proposed as a 
mechanism of pathogenesis [106] and associated to tumorigenic potential [107, 108]. On 
the contrary, suppressive effects have been ascribed to Tat and taken as explanation of the 
immune impairment occurring during HIV-infection. Tat-mediated inhibition of 
proliferation [109, 110] would be due to the inhibition of CD26 activity [111] and the 
enhanced release of the suppressive cytokine IL-10 [112]. Thus, it has been proposed that 
Tat may induce pro-apoptotic signals through JNK and it mediates cell proliferation 
through the ERK pathway, whose activation is required for cell growth [113, 114]. The 
pleiotropic effects of Tat on these two pathways are confirmed by the observation that 
rapamycin, which inhibits mTor activity, abolished Tat-mediated activation of JNK, while 
it enhanced Tat-mediated activation of ERK/MAPK, suggesting the involvement of mTOR 
in Tat-induced signalling [91]  (Figure 1.11). 
 
Figure 1.11. Differential activation of MAP kinases by distinct Nox pathways. Adapted by [114] 
 
While Tat inhibits cells proliferation and induces apoptosis at high concentrations [98, 99, 
115, 116], at lower physiological concentrations (nM) Tat promotes CD4
+
 T cells survival 
[117, 118].  
This is confirmed by the observation that Tat, expressed on the surface of heterologous 
cells, activates and induces proliferation of human peripheral blood mononuclear cells 
(PBMCs), in a mechanism dependent by CD3 stimulation [105].  
Several authors have suggested that the generalized decrease in CD127 expression on 
CD8
+
 T cells in HIV-infected patients is the result of chronic antigen stimulation and 
immune activation [119, 120]. Indeed, HIV-Tat protein and IL-7 seem to act 
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synergistically to down-regulate CD127 on CD8
+
 T cells isolated from healthy volunteers. 
This synergism appears to be mediated, at least in part, by JAKs as addition of JAK 
inhibitor 1 completely blocked IL-7 ability to down-regulate CD127 and abolished synergy 
with Tat. Importantly, Tat has no effect on CD8
+
 T cells viability [121]. 
In addition to these effects on CD4
+
 and CD8
+
 T cells programming and homeostasis, Tat 
can modulate antigen presentation at different levels. Indeed, Tat modifies the composition 
and the activity of the proteasome, affecting the generation and recognition of CTL peptide 
epitopes [122, 123]. In particular, Tat increases the presentation of subdominants epitopes 
at the expense of the immunodominant ones [123]. Furthermore, some studies demonstrate 
that Tat enhances the release of several cytokines in monocytes, macrophages and DCs 
[124-127], as well as to up regulate costimulatory molecules such as CD40, CD80, CD83 
and CD86 [124]. However, recently, a Tat-mediated enhancement of HLA-ABC and HLA-
DR expression on DCs has been demonstrated [124]. 
DC are professional APCs actively involved in CTLs development, and CD4
+
 T cells 
support CD8
+
 T lymphocytes in their generation and maintenance of effector and memory 
subsets; thus, it is reasonable to think that Tat-mediated effects on these cell types could 
also affect the CD8
+
 T cell response and, thus, the control of infection. 
The immunomodulatory properties displayed by Tat make this molecule an attractive 
adjuvant for other antigens. Indeed, since Tat plays a key role in HIV life and its 
progression, it can be considered a perfect candidate to preventive and therapeutic AIDS 
vaccine.  
Safety and immunogenicity data collected in several animals models [128, 129], in 
addition with results obtained in Tat-vaccinated monkeys, that showed a viremia at 
undetectable levels and absence of CD4
+
 decline after challenge with SHIV viruses [130, 
131],  supported the development of a Tat-based vaccine.  
A preventive and a therapeutic phase I trials have already been performed in parallel with 
the recombinant biologically active HIV-1 Tat (86aa) to evaluate safety and 
immunogenicity [132]. After the successful achievement of the end-points, Tat vaccine 
was administered to 87 ART-treated HIV-positive individuals, both in Italy and South 
Africa, during phase II clinical trial [133]. Promising results are obtained such as a 
restoration of immune functions by the reversion of CD4
+
 T cells and B lymphocytes loss 
in Tat-immunized individuals. In 2013, a second Tat-based vaccine that utilizes a Tat 
variant isolated from a group of HIV controllers African patients (Tat Oyi) has entered in 
phase I clinical trial in France [134]. 
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2. AIMS 
 
The HIV infection is associated with a state of chronic immune activation that drives the 
general de-regulation of the immune system. T cells of HIV positive people are indeed 
characterized by an active proliferation, loss of functionality and susceptibility to 
apoptosis. These phenomena do not involve only HIV-infected or HIV-specific T cells, but 
are generalized to the all T lymphocyte compartment. The causes of this phenomena are 
not yet understood, although the contribution of HIV viral proteins (alone or in 
combination with other cellular factors) may play a key role in the modulation of T cell 
activities. It is known that the HIV-Tat protein, the transactivator of HIV gene expression, 
is essential for viral replication [135-137] and, therefore, for establishment of infection and 
virus reactivation [138-140]. Upon virus entry into cells, Tat is expressed by proviral DNA 
prior to virus integration [141], and it is released extracellularly  by a leaderless secretory 
pathway [138, 139]. Upon release, Tat binds heparan sulphate proteoglycans of the 
extracellular matrix and integrins, and via this receptors binding, could enter cells very 
efficiently. 
In previous studies it has been demonstrated that the Tat protein modulates cellular 
responses to heterologous antigens [142] suggesting that Tat displays immunomodulatory 
features, only partially characterized at molecular level, affecting CD4- and CD8-mediated 
cellular responses. In addition, it has been found that Tat increases the activation and 
maintenance of antigen specific T cells in mice [143]. These preliminary studies suggest 
that Tat may affect CD4
+
 and CD8
+
 T cells. Thus, the identification of the role of Tat on 
signals and transcriptional programs of T cells differentiation, survival and proliferation, is 
a key to clarify the role of this HIV protein on disease progression and immune 
dysfunctions caused by HIV infection. In addition, immunomodulatory proprieties of Tat 
may be used to enhance vaccines efficacy. 
The specific aims of my study are: 
1. The evaluation of the effects of Tat on cytokines production by T cells. 
2. The evaluation of the effects of Tat on proliferation and viability of T cells. 
3. The evaluation of the effects of Tat on transcriptional profile of T cells. 
4. The evaluation of the effects of Tat on phenotype of T cells. 
5. The evaluation of the effects of Tat on the expansion of antigen-specific T cells. 
6. The evaluation of the effects of Tat on the expansion of HSV1-specific CD8+ T 
cells after immunization with recombinant Herpes Simplex vector. 
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7. The evaluation of the effects of Tat on HSV1 specific CD8+ T cells memory 
subpopulations after immunization with recombinant Herpes Simplex vector. 
 
In the table below are summarized the methods for each specific aim; details in “Material 
and Methods” section. 
 
Effect of Tat on T cells  Methods Specific aims 
Cytokines release Elispot - Bio-Plex 1 
Protein expression 
Western Blotting - Intracellular 
Staining 
1-3 
CTLs cytotoxicity 
51
Cr-release assay 5 
Phenotype FACS 4-6-7 
mRNA expression SYBR green quantitative PCR 3 
Proliferative capacity MTT assay - CFSE assay 2 
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3. RESULTS 
 
3.1 Tat enhances the production of IL-2 in PBLs 
 
Several studies have reported the capacity of the HIV-1 Tat protein to activate PBLs and 
CD4
+ 
T cells resulting in an increase of IL-2 production when cells were exposed to 
different stimuli, including antibodies specific for the CD3 and CD28 (anti-CD3/CD28) 
receptors that mimic physiological T cell activation [92, 102-104, 144]. To confirm these 
results, we first sought to determine whether the amounts of secreted Tat usually found in 
vivo may account for this effect. To this aim, PBLs from healthy donors were activated 
with anti-CD3/CD28 in the absence or presence of different doses of Tat (from 0.001 
µg/ml to 1 µg/ml), and IL-2 mRNA levels were measured after 4 hours by qPCR (Scheme 
1).  
Scheme 1 
 
As shown in Figure 3.1a, a 75 fold-increase of IL-2 mRNA was observed in PBLs 
activated in the absence of Tat compared to untreated PBLs, while the presence of Tat 
induced a 150-200 fold-increase of IL-2 mRNA expression. This effect was observed at 
similar levels for all Tat doses except at 0.001 µg/ml. Similar results were obtained at 24 
hours after activation (Figure 3.1b), demonstrating that this effect is long lasting. As the 
highest fold-increase was observed at 0.1 µg/ml of Tat, this dose was chosen to perform 
the subsequent experiments. Of note, this concentration is within the range of the 
physiological concentration of Tat found in sera of HIV-positive individuals. Moreover, to 
assess whether the increased mRNA levels resulted in increased cytokine release, IL-2 
secretion from PBLs was evaluated by Bio-Plex at 24 hours after activation.  
As shown in Figure 3.1c, a 2 fold increase of the production of IL-2 was detected in PBLs 
activated in the presence of Tat. 
PBLs Anti-CD3/CD28;
 Tat
4 or 24 hours
IL-2 mRNA and protein expression
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To further confirm that the increase of the production of IL-2 was mediated by the 
presence of Tat, similar experiments were performed in the presence of anti-Tat antibodies 
obtained from sera of immunized mice. As shown in Figure 3.2, the incubation with anti-
Tat antibodies during the treatment, abolished the Tat-mediated effect.  
 
Figure 3.1. Tat enhances IL-2 production in activated PBLs. (a, b) PBLs from healthy donors (n=6) 
activated with anti-CD3/CD28 were cultured in the absence or presence of the indicated concentrations of 
Tat for 4 (a) or 24 (b) hours and IL-2 mRNA levels were quantified by qPCR and normalized to untreated 
cells. (c) PBLs from healthy donors (n=6) unstimulated or activated with anti-CD3/CD28 were cultured in 
the absence or presence of Tat (0.1 µg/ml). After 24 hours IL-2 release was quantified by Bio-Plex and 
normalized to untreated cells. Data are presented as mean ± SEM. For statistical analysis two-tailed 
Wilcoxon signed rank test was used. *P<0.05: Tat-treated cells compared to Tat-untreated control cells. 
Figure 3.2. Tat-mediated increase of IL-2 production in activated PBLs is abolished by anti-Tat 
antibodies. PBLs from healthy donors unstimulated or activated with anti-CD3/CD28 were cultured in the 
absence or presence of Tat (0.1 µg/ml) and anti-Tat immune antibodies. IL-2 mRNA levels were quantified 
by qPCR and normalized to untreated cells.  The results of one representative experiment out of three are 
shown. 
+
+
-
+
-
+
0
20
40
60
80
100
120
140
IL
-2
 m
R
N
A
re
la
ti
v
e
 e
x
p
re
s
s
io
n
CD3/CD28
0.1 mg/ml Tat
Anti-Tat Ab
-
-
-
+
-
-
+
+
+
0
100
200
300
400
500
- 0.001 0.01 0.1 1
IL
-2
 m
R
N
A
 r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 
0
100
200
300
400
500
- 0.1 1mg/ml Tat
* **
*
*
0
200
400
600
800
1000
R
e
la
ti
v
e
 I
L
-2
 r
e
le
a
s
e
CD3/CD28
0,1 μg/ml Tat
-
-
+
-
+
+
*
a
. 
b
. 
c
. 
Results 
32 
 
3.2 Tat enhances IL-2 and IFNγ production in CD8+ and CD4+ T cells 
 
We sought to determine whether Tat specifically affects cytokine production in activated 
CD4
+ 
and CD8
+
 T cells. To this aim, first the expression of IL-2 mRNA was evaluated in 
activated CD4
+ 
and
 
in CD8
+ 
T cells activated alone or purified from activated PBLs 
(Scheme 2a and 2b). 
 
  
Scheme 2 
 
Interestingly, Tat significantly increased IL-2 mRNA in both CD8
+
 T cells activated alone 
(Figure 3.3a) or purified from activated PBLs (Figure 3.3b).  Moreover, consistently with 
literature results [102], the presence of Tat during the stimulation induced a significant 
increase of IL-2 mRNA expression in CD4
+
 T cells (Figure 3.3c).  
PBLs
CD8+
Anti-CD3/CD28;
 Tat
PBLs
Anti-CD3/CD28;
 Tat
CD8+ /CD4+
4  hours
IL-2 and IFNγ mRNA and protein expression
4  hours
IL-2 and IFNγ mRNA and protein expression
a b 
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Figure 3.3. Tat enhances IL-2 production in CD8+ and CD4+ T cells. (a) CD8+ T cells were purified from 
PBLs from healthy donors (n=6) and activated with anti-CD3/CD28 in the presence or absence of 0.1µg/ml 
of Tat for 4 hours. (b) PBLs from healthy donors (n=6) were activated with anti-CD3/CD28 in the presence 
or absence of 0.1µg/ml of Tat. After 4 hours of stimulation, CD8
+ 
T cells were purified. (c) CD4
+
 T cells 
were purified from PBLs from healthy donors (n=6) and activated with anti-CD3/CD28 in the presence or 
absence of 0.1µg/ml of Tat for 4 hours. IL-2 mRNA levels were quantified by qPCR and normalized to 
untreated cells. Data are presented as mean ± SEM. For statistical analysis two-tailed Wilcoxon signed rank 
test was used. *P<0.05: Tat-treated cells compared to control cells. 
 
 
 
To confirm these results, the IL-2 production was also evaluated by intracellular cytokine 
staining (ICS). To this aim, PBLs from healthy subjects were activated with anti-
CD3/CD28 in presence or absence of Tat (0.1 and 10 µg/ml), and the secretion of IL-2 was 
measured in CD8
+
 and CD4
+
 T cells at 6 and 18 hours after treatment (Figure 3.4a and 
3.4b). There was no effect of Tat on IL-2 production by CD8
+
 and CD4
+
 T cells at 6 hours 
after stimulation (data not shown). However, an average of 1.5-time fold increase of IL-2 
secretion was observed after 18 hours of stimulation in both CD8
+
 and CD4
+
 T cells 
activated in the presence of 0.1 and 10 µg/ml of Tat compared to CD8
+
 and CD4
+
 T cells 
activated without Tat. 
 
Taken together, these data demonstrate for the first time that Tat increases the 
production of IL-2 in CD8
+
 T cells. 
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Figure 3.4. Tat enhances percentage of IL-2
+ 
CD8
+
 and IL-2
+ 
CD4
+
 T cells. PBLs from healthy donors 
(n=7) were activated with anti-CD3/CD28 in the presence or absence of different concentrations of Tat for 18 
hours. Percentages of CD8
+
 (a) or CD4
+
 (b) T cells secreting IL-2 were determined by ICS. Data are 
presented as mean ± SEM. For statistical analysis two-tailed Wilcoxon signed rank test was used. *P<0.05: 
Tat-treated cells compared to control cells.  
 
 
Thus, we next investigated whether the presence of Tat during the activation of T cells 
could also modulate IFNγ production. To this aim, first the expression of IFNγ mRNA was 
evaluated in activated CD4
+ 
and
 
in CD8
+ 
T cells activated alone or purified from activated 
PBLs. The presence of Tat during the stimulation dramatically enhanced IFNγ production 
in CD8
+
 T purified from activated PBLs and in CD4
+
 T cells activated alone but not in 
CD8
+
 T cells activated alone (Figure 3.5 a-c).  
 
Taken together, these results demonstrate that physiological concentrations of Tat 
enhance the production of IL-2 and IFNγ in both CD8+ and CD4+ T cells activated 
with anti-CD3/CD28. 
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Figure 3.5. Tat enhances IFNγ production in CD8+ and CD4+ T cells. (a) CD8+ T cells were purified from 
PBLs from healthy donors (n=6) and activated with anti-CD3/CD28 in the presence or absence of 0.1µg/ml 
of Tat for 4 hours. (b) PBLs from healthy donors (n=6) were activated with anti-CD3/CD28 in the presence 
or absence of 0.1µg/ml of Tat. After 4 hours of stimulation, CD8
+
 T cells were purified. (c) CD4
+
 T cells 
were purified from PBLs from healthy donors (n=6) and activated with anti-CD3/CD28 in the presence or 
absence of 0.1µg/ml of Tat for 4 hours. IFNγ mRNA levels were quantified by qPCR and normalized to 
untreated cells. Data are presented as mean ± SEM. For statistical analysis two-tailed Wilcoxon signed rank 
test was used. *P<0.05: Tat-treated cells compared to control cells. 
 
3.3 Tat does not affect the proliferation of activated CD8
+
 and CD4
+
 T cells 
 
We next evaluated whether the presence of Tat during the activation of T cells resulted in 
an enhanced proliferation. To this purpose, PBLs activated with different stimuli (anti-
CD3/CD28, PHA, PMA and LPS) in the absence or presence of Tat were cultured up to six 
days, and PBLs, CD8
+
 and CD4
+
 T cell proliferation was measured by CFSE staining and 
MTT assay (Scheme 3).  
 
Scheme 3 
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As shown in Figure 3.6, the presence of Tat did not affect the proliferation of PBLs 
activated with the indicated stimuli. In addition, Tat did not affect proliferation of CD4
+
 
and CD8
+
 T cells activated with CD3/CD28 (Figure 3.7). This is consistent with previous 
reports showing that soluble Tat was ineffective in enhancing anti-CD3/CD28 induced 
proliferation [102, 115].  
 
 
 
 
Figure 3.6. Tat does not affect T cell proliferation. PBLs from healthy donors were activated with 
different kind of stimuli: PHA, PMA + Ionomycin, LPS and anti-CD3/CD28, in the presence or absence of 
different concentrations of Tat, and cultured up to six days. Cell proliferation was measured by MTT assay. 
One representative experiment out of three is shown. 
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Figure 3.7. Tat does not affect CD4+ and CD8+ T cells proliferation. PBLs from healthy donors were 
activated with anti-CD3/CD28 in the absence or presence of 0.1 µg/ml of Tat and cultured up to six days. 
Proliferation of CD4
+
 and CD8
+
T cells was assessed by CFSE staining. One representative experiment out of 
three is shown. 
 
3.4 Tat affects the expression of key transcription factors in activated CD8
+ 
T cells 
 
T-bet and Eomes are transcription factors (TFs) that are up-regulated during HIV infection 
[79] and that control IFNγ production [45, 145]. Since we have shown here that Tat 
enhances IFNγ production in human CD8+ T cells stimulated by TCR engagement, we next 
characterized the expression of T-bet and Eomes in CD8
+
 T cells activated alone (Scheme 
4a) or purified from activated PBLs (Scheme 4b) cultured in the absence or presence of 
Tat. Moreover, the expression of other TFs important for T cell functionality, survival and 
programming, as Blimp-1, Bcl-6 and Bcl-2, was analyzed. 
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As shown in Figure 3.8a the presence of Tat during the stimulation did not change at a 
significant level the transcriptional profile of CD8
+
 T cells activated alone, as the 
expression of all the TFs investigated was not affected by Tat-treatment. Conversely, 
mRNA levels of all the five TFs taken into consideration were significantly increased in 
CD8
+ 
T cells purified from PBLs activated in the presence of Tat (Figure 3.8b). Notably, 
Tat up-regulated not only genes required for effector functions (as T-bet, Eomes, Blimp-1), 
but also TFs important for memory development (Bcl-6 and Eomes) and T cell survival 
(Bcl-2). Moreover, these results demonstrate that Tat does not directly affect CD8
+
 T cells, 
but requires other lymphocyte subpopulations to modulate the TFs expression in CD8
+
 T 
cells. Finally, to assess whether the increased mRNA expression correlated with an 
increased protein expression, T-bet and Eomes proteins were evaluated by western blotting 
in CD8
+
 T cells at 24 and 48 hours after activation. Notably, CD8
+
 T cells purified from 
PBLs activated in the presence of Tat exhibited an increase of T-bet and Eomes expression 
48 hours after the activation (Figure 3.9). 
 
Taken together, these data demonstrate that Tat favors the activation of CD8
+
 T cells 
affecting the expression of TFs crucial for T cell programming and functionality. Of 
note, this Tat-mediated effect required the help of other lymphocyte subpopulations. 
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Figure 3.8. The effect of Tat on the transcriptional profile of CD8
+
 T cells. (a) CD8
+
 T cells were purified  
from PBLs of healthy donors (n=8), activated with anti-CD3/CD28 and cultured in the absence or presence 
of 0.1µg/ml of Tat. After 4 hours, mRNA levels of the indicated molecules were quantified by qPCR and 
normalized to untreated cells. (b) PBLs from healthy donors (n=8) activated with anti-CD3/CD28 were 
cultured in the absence or presence of Tat (0.1 µg/ml). After 4 hours, CD8
+
 T cells were purified and mRNA 
levels of the indicated molecules were quantified by qPCR and normalized to untreated cells. Data are 
presented as mean ± SEM. For statistical analysis two-tailed Wilcoxon signed rank test was used. *P<0.05: 
Tat-treated cells compared to Tat-untreated control cells. 
Figure 3.9. Tat enhances T-bet and Eomes protein expression in CD8
+
 T cells. PBLs from healthy donors 
unstimulated or activated with anti-CD3/CD28 were cultured in the absence or presence of Tat (0.1 µg/ml). 
(a) CD8
+
 T cells were purified after 24 and 48 hours, and expression of T-bet and Eomes proteins was 
assessed by western blotting. The results of one representative experiment out of three are shown. 
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3.5 Tat affects the expression of key transcription factors in activated CD4
+ 
T cells 
 
As we have shown that the Tat-mediated up-regulation of T-bet, Eomes, Blimp-1, Bcl-6, 
Bcl-2 in CD8
+ 
T cells requires the presence of other T lymphocyte subpopulations, we 
sought to determine whether Tat could also modulate the transcriptional profile of CD4
+ 
T 
lymphocytes which are known to contribute to the activation of CD8
+
 T cells. To this aim, 
purified CD4
+ 
T cells were activated, in the absence or presence of Tat, with anti-
CD3/CD28, and the expression of the above mentioned TFs was evaluated 4 hours after 
activation (Scheme 5).  
Scheme 5 
 
Notably, a 15.5-fold increase of T-bet mRNA was observed in CD4
+ 
T cells activated in 
the presence of Tat as compared to a 7-fold increase in CD4
+ 
T cells activated without Tat. 
Moreover, Tat-treatment significantly increased the expression of Blimp-1, Bcl-6 and Bcl-
2 but not of Eomes (Figure 3.10). Finally, to assess whether the increased mRNA 
expression correlated with an increased protein expression, T-bet protein was evaluated by 
western blotting in CD4
+
 T cells at 24 and 48 hours after activation. Notably, CD4
+
 T cells 
activated in the presence of Tat exhibited an increase of T-bet expression after 48 hours 
after the stimulation (Figure 3.11).  
 
Thus, these data provide evidence that Tat favors the activation of CD4
+ 
T cells up-
regulating the expression of key TFs. 
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Figure 3.10. The effect of Tat on the transcriptional profile of CD4+ T cells.  CD4+ T cells were purified  
from PBLs of healthy donors (n=8), activated with anti-CD3/CD28 and cultured in the absence or presence 
of 0.1µg/ml of Tat. After 4 hours, mRNA levels of the indicated molecules were quantified by qPCR and 
normalized to untreated cells. Data are presented as mean ± SEM. For statistical analysis two-tailed 
Wilcoxon signed rank test was used. *P<0.05: Tat-treated cells compared to Tat-untreated control cells. 
 
 
 
Figure 3.11. Tat enhances T-bet and Eomes protein expression in CD4
+
 T cells. CD4
+
 T cells were 
purified from PBLs of healthy donors and were activated with anti-CD3/CD28 were cultured in the absence 
or presence of Tat (0.1 µg/ml). After 24 and 48 hours, the expression of T-bet protein was assessed by 
western blotting. The results of one representative experiment out of three are shown. 
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3.6 αvβ3 and α5β1 integrins blocking affects Tat-mediated effect on the transcriptional 
profile in activated PBLs 
 
Extracellular Tat is known to activate CD4
+
 T cells by binding with its RGD region the 
αvβ3 and α5β1 integrins [115]. To understand whether the enhancement of TFs expression 
induced by Tat was integrin-mediated, PBLs were pre-incubated with Abs directed against 
αvβ3 and α5β1 and subsequently activated with anti-CD3/CD28 in the absence or presence 
of Tat. The effect of Tat was significantly inhibited by integrins blocking (Figure 3.12), 
indicating that the binding of Tat to αvβ3 and α5β1 is required for the enhancement of TFs 
expression. 
 
 
Figure 3.12. The effect of Tat is inhibited by integrins blocking. PBLs from healthy donors (n=3) 
unstimulated or activated with anti-CD3/CD28 were cultured in the absence or presence of Tat (0.1 µg/ml). 
PBLs were pre-incubated with anti-integrins monoclonal antibodies for 1 hour at room temperature before 
activation with anti-CD3/CD28 and Tat treatment. After 4 hours, CD8+ T cells were purified and mRNA 
levels of the indicated molecules were quantified by qPCR and normalized to untreated cells. Data are 
presented as mean ± SEM. 
 
Thus we next investigated whether the Tat effects on CD8
+ 
T cells were mediated by cell-
to-cell contact or by soluble molecules released by PBLs activated in the presence of Tat. 
To this aim, purified CD8
+ 
T cells were stimulated with anti-CD3/CD28 and co-cultured 
with supernatant derived from PBLs activated in the absence or presence of Tat. As it is 
also possible that Tat might directly act on CD8
+
 T cells in synergy with other soluble 
molecules, we included a condition where Tat was added together with supernatant derived 
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derived from PBLs activated in the presence of Tat was unable to increase IL-2,  IFNγ and 
T-bet expression. 
 
Figure 3.13. Supernatants from PBLs treated with Tat did not enhance IFNγ, IL-2 and T-bet 
expression in CD8
+
 T cells.  CD8
+
 T cells were purified  from PBLs of healthy donors (n=7), activated with 
anti-CD3/CD28 and cultured with the supernatant from PBLs activated with anti-CD3/CD28 in the absence 
or presence of 0.1µg/ml of Tat for 4 hours., mRNA levels of IFNγ (a), IL-2 (b) and T-bet (c) were quantified 
by qPCR and normalized to untreated cells. 
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However we can not exclude that these negative results may be due to the experimental 
conditions. Thus, further experiments are required to clarify the role of other immune cell 
subpopulations on the activation of CD8
+
 T cells. 
 
3.7 Tat down regulates CD127 expression and modulates the fate of T cells 
 
It has been recently shown that the expression of T-bet and Eomes in memory CD8
+
 T 
cells from HIV-infected individuals is associated with decreased expression of the IL-7 
receptor CD127, and increased IFNγ and granzyme B levels [29]. As Tat up-regulates T-
bet and Eomes (Figures 3.8 and 3.9) as well as IFNγ (Figure 3.5) and granzyme B 
production (Figure 3.15), we then assessed whether Tat could affect CD127 expression in 
activated CD8
+
 T cells. Moreover, we also measured the expression of CD25, the alpha 
chain of the receptor for IL-2, whose production is modulated by Tat. As shown in Figure 
3.14a, activation of PBLs with anti-CD3/CD28 increased the expression of CD25 and 
decreased the expression of CD127 on CD8
+
 T cells. The presence of Tat did not affect the 
percentage of CD8
+
 T cells expressing CD25, while it decreased the fraction of CD8
+
 T 
lymphocytes expressing CD127. Interestingly, this effect was mediated by Tat in both 
unstimulated and activated CD8
+
 T cells. 
As T-bet, Eomes, Bcl-6, Blimp-1 and Bcl-2 regulate at different extent the T cell 
programming and memory development, we next sought to determine the fate of CD8
+
 T 
cells exposed for longer time to Tat. To this aim, we evaluated the expression of CD45RO 
and CD27, two markers of memory cells, in unstimulated or activated PBLs cultured for up 
to 8 days in the absence or presence of Tat. In long-term cell cultures the presence of Tat 
did not modulate the expression of CD45RO, while it increased the expression of CD27 in 
activated but not in unstimulated CD8
+
 T cells (Figure 3.14b). Interestingly, CD27 
expression was not affected by Tat after 24 or 48 hours of culture (not shown).  
 
These results suggest that the Tat-mediated modulation of T-bet, Eomes and the 
other TFs may be associated with the CD127 down-regulation and the accumulation 
of CD27
+
CD8
+
 T cells.   
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Figure 3.14. Tat modulates the phenotype of CD8
+
 T cells. PBLs from healthy donors (n=6) unstimulated 
or activated with anti-CD3/CD28 were cultured in the absence or presence of Tat (0.1 µg/ml). (a) After 24 
hours, the percentage of CD8
+
 T cells expressing CD25 and CD127 was measured. (b) After 8 days, the 
percentage of CD8
+
 T cells expressing CD45RO and CD27 was measured. The results of one representative 
experiment out of six are shown. 
 
 
3.8 Tat favors the activation of antigen-specific naïve and memory CD8
+ 
T cells 
 
We next assessed whether the presence of Tat in long-term cell cultures could also affect 
activation and functionality of antigen-specific memory and naïve CD8
+
 T cells. To this 
aim, PBLs obtained from healthy HLA class I-typed EBV-seropositive donors were 
stimulated ex-vivo with cells pulsed with EBV-derived CTL peptide epitopes in the 
absence or presence of Tat. Specifically, PBLs were stimulated with the subdominant 
HLA-A2-restricted CLGGLLTMV (CLG) or YLQQNWWTL (YLQ) epitope [146, 147] or 
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with the immunodominant HLA-A11-restricted IVTDFSVIK (IVT) epitope [148]. The 
cytotoxic activity of each CTL culture generated in the absence or presence of Tat was 
tested against autologous PHA-blasts, pulsed or not with the relevant synthetic peptide, in 
a standard 
51
Cr-release assay. As shown in Figure 3.15a-c, all the three CTL cultures 
generated in the presence of Tat exhibited higher percentages of specific lysis compared to 
those generated in the absence of Tat.  
To determine whether the Tat protein favors also the activation of naïve T cells, PBLs from 
HLA-A2 healthy donors were stimulated with the synthetic ELT peptide in the absence or 
presence of the Tat protein. The ELT (ELTLGEFLKL) peptide is a CTL epitope, presented 
by HLA-A2 [149, 150], belonging to the anti-apoptotic protein survivin that is 
overexpressed in tumor cells [151]. No T-cell reactivity against this epitope is normally 
detected in healthy patients [151]. The specificity of CTL cultures was tested against PHA-
blasts, pulsed or not with the ELT-peptide, by 
51
Cr-release assays (Figure 3.15d). HLA-A2 
positive PHA-blasts pulsed with the ELT-peptide were efficiently lysed only by CTL 
cultures generated in the presence of Tat, demonstrating that Tat favors the priming of 
naïve CD8
+ 
T cells. 
These observations suggest that Tat favors the activation of CD8
+ 
T cells, but do not clarify 
whether the increased cytotoxic activity observed in CTL cultures generated in the 
presence of Tat depends on a higher number or a higher functionality of epitope-specific 
CD8
+ 
T cells. To address this issue, CTL cultures specific for the HLA-A2-restricted CLG 
epitope were generated in the absence of Tat and then were left untreated or pre-incubated 
with the Tat protein 24/48 hours before the cytotoxic activity. As shown in Figure 3.15e, 
CTL cultures lysed target cells at similar levels, suggesting that Tat does not enhance 
effector functions, but rather must be present at the time of the priming thus favouring CTL 
expansion. To confirm this hypothesis, CLG- and YLQ-specific CTLs generated in the 
absence or presence of Tat were assayed in IFNγ and granzyme B Elispot assays to 
evaluate differences in the number of antigen specific T cells. As shown in Figure 3.15f, 
CTL cultures generated in the presence of Tat exhibited higher numbers of both IFNγ and 
granzyme B CLG- and YLQ-specific CTLs, suggesting that Tat favors the expansion of 
epitope-specific and actively secreting CD8
+
 T cells.  
 
Taken together, these data demonstrate that Tat favors the priming of naïve CD8
+
 T 
cells and the expansion of memory CD8
+
 T cells. 
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Figure 3.15. Tat favors the activation of antigen-specific memory and naïve CTLs. (a-c) CTL cultures 
specific for YLQ (a), CLG (b), or IVT (c) EBV-derived epitopes were generated, in the absence or presence 
of Tat (0.1 µg/ml), from lymphocytes purified from EBV-positive donors and tested for their cytotoxic 
activity by 51Cr-release assay against autologous unpulsed or peptide-pulsed PHA-blasts (E:T ratio 10:1). (d) 
CTL cultures specific for the ELT survivin-derived epitope were generated, in the absence or presence of Tat 
(0.1 µg/ml), from lymphocytes purified from healthy donors and tested for their cytotoxic activity by 51Cr-
release assay against autologous unpulsed or peptide-pulsed PHA-blasts (E:T ratio 10:1). (e) CTL cultures 
specific for the CLG peptide epitope were generated from lymphocytes purified from EBV-positive donors. 
24 or 48 hours before the 51Cr-release assay (E:T ratio 10:1), CTL cultures were treated with the Tat protein 
(0.1 µg/ml). (f) CTL cultures specific for YLQ and CLG EBV-derived epitopes were generated, in the 
absence or presence of Tat (0.1 µg/ml), from lymphocytes purified from EBV-positive donors and tested for 
their IFNγ and granzyme B release by Elispot assay. The results of one representative experiment out of five 
are shown. 
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3.9 Tat does not affect the expression of IL-2 and IFNγ in unstimulated CD8+ and 
CD4
+
 T cells 
 
We demonstrate that Tat changes some specific phenotype markers and enhances the 
activation and functionality of CD8
+ 
and CD4
+ 
T cells stimulated by TCR engagement 
(different CD8
 
peptide epitopes and anti-CD3/CD28 stimulation). Thus, we sought to 
determine whether Tat could also modulate unstimulated T cells. 
To this aim, IFNγ and IL-2 mRNA levels were measured in unstimulated CD8+ and CD4+ 
T cells cultured in the absence or presence of Tat without any activation. After 4 hours of 
treatment, the expression of IFNγ and IL-2 mRNA levels was not significantly affected by 
the presence of Tat (Figure 3.16 a-c). 
Figure 3.16. Tat does not enhance IFNγ and IL-2 production in unstimulated CD8+ and CD4+ T cells. 
(a) CD8
+
 T cells were purified  from PBLs of healthy donors (n=6), and cultured in the absence or presence 
of 0.1µg/ml of Tat. After 4 hours,  IL-2 and IFNγ mRNA levels were quantified by qPCR and normalized to 
untreated cells. (b) PBLs from healthy donors (n=6) were cultured in the absence or presence of Tat (0.1 
µg/ml). After 4 hours, CD8
+
 T cells were purified and IL-2 and IFNγ mRNA levels were quantified by qPCR 
and normalized to untreated cells. (c) CD4
+
 T cells were purified from PBLs from healthy donors (n=6) and 
cultured in the absence or presence of 0.1µg/ml of Tat. After 4 hours,  IL-2 and IFNγ mRNA levels were 
quantified by qPCR and normalized to untreated cells. Data are presented as mean ± SEM.  
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3.10 Tat does not modulate the transcriptional profile of unstimulated CD8
+
 and 
CD4
+
 T cells 
 
We next investigated whether Tat could also modulate the basal transcriptional prolife of 
unstimulated CD8
+
 and CD4
+
 T cells. To this aim, T-bet, Eomes, Blimp-1, Bcl-6 and Bcl-2 
mRNA levels were measured in purified CD8
+
 (treated alone or sorted from treated PBLs) 
and CD4
+
 T cells cultured in the absence or presence of Tat for 4 hours. After 4 hours of 
treatment, the expression of the analyzed TFs was not significantly affected by the 
presence of Tat (Figure 3.17), although the obtained results show a tendency of a Tat-
mediated enhancement of the two memory-related TFs Eomes and Bcl-6 in CD8
+
 T cells 
purified from Tat-treated PBLs (Figure 3.17b).  
 
Thus, these results suggest that Tat alone does not modulate the transcriptional 
profile of CD8
+
 and CD4
+
 T cells after four hours of treatment.  
Figure 3.17. Tat does not modulate the transcriptional profile of unstimulated CD8
+
 and CD4
+
 T cells. 
(a) CD8
+
 T cells were purified  from PBLs of healthy donors (n=8) and cultured in the absence or presence of 
0.1µg/ml of Tat. After 4 hours, mRNA levels of the indicated molecules were quantified by qPCR and 
normalized to untreated cells. (b) PBLs from healthy donors (n=8) were cultured in the absence or presence 
of Tat (0.1 µg/ml). After 4 hours, CD8
+
 T cells were purified and mRNA levels of the indicated molecules 
were quantified by qPCR and normalized to untreated cells. (c) CD4
+
 T cells were purified  from PBLs of 
healthy donors (n=8) and cultured in the absence or presence of 0.1µg/ml of Tat. After 4 hours, mRNA levels 
of the indicated molecules were quantified by qPCR and normalized to untreated cells.  Data are presented as 
mean ± SEM.  
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3.11 Tat modulates T-bet and Eomes mRNA expression in unstimulated CD8
+
 and 
CD4
+
 T cells after 24 hours of treatment (Preliminary data) 
 
It has been show that after 4 hours of treatment, Tat could not modulate, in unstimulated T 
cells, any of the TFs taken into consideration. However, the expression of these TFs in 
unstimulated T cells may require longer exposition to Tat. To this aim, T-bet and Eomes 
mRNA levels were measured in purified CD8
+
 (treated alone or sorted from treated PBLs) 
and CD4
+
 T cells cultured in the absence or presence of Tat for 24 hours.  Interestingly, 
after 24 hours of stimulation, CD8
+
 T cells purified from PBLs cultured with Tat showed a 
significant up-regulation of T-bet and Eomes compared to CD8
+
 T cells cultured without 
Tat (Figure 3.18b), however, CD8
+
 T cells cultured alone were not affected by treatment 
with Tat (Figure 3.18a). Furthermore, T-bet was also significantly up-regulated by Tat in 
CD4
+
 T cells (Figure 3.18c). Finally, our results show a tendency for the down-regulation 
of Eomes expression in CD4
+
 T cells (fold change = 0.5, p=0.06) that however did not 
reach statistical significance.  
Figure 3.18. Tat modulates T-bet and Eomes mRNA expression in unstimulated CD8
+
 and CD4
+
 T 
cells after 24 hours of treatment. (a) CD8
+
 T cells were purified  from PBLs of healthy donors (n=7) and 
cultured in the absence or presence of 0.1µg/ml of Tat. After 24 hours, mRNA levels of the indicated 
molecules were quantified by qPCR and normalized to untreated cells. (b) PBLs from healthy donors (n=8) 
were cultured in the absence or presence of Tat (0.1 µg/ml). After 24 hours, CD8
+
 T cells were purified and 
mRNA levels of the indicated molecules were quantified by qPCR and normalized to untreated cells. (c) 
CD4
+
 T cells were purified  from PBLs of healthy donors (n=8) and cultured in the absence or presence of 
0.1µg/ml of Tat. After 24 hours, mRNA levels of the indicated molecules were quantified by qPCR and 
normalized to untreated cells.  Data are presented as mean ± SEM. Data are presented as mean ± SEM. For 
statistical analysis two-tailed Wilcoxon signed rank test was used. *P<0.05: Tat-treated cells compared to 
Tat-untreated control cells. 
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3.12 Immunization with an attenuated HSV1 vector expressing Tat increases the 
number of HSV1-specific CD8
+
 T cells and favors the development of effector 
memory T cells 
 
The above reported results indicate that Tat favors the activation of CD8
+
 T cells. 
Moreover, it has been previously demonstrated that Tat broadens T cell responses to co-
antigens [142]. Thus, these observations suggest that Tat may be used as an adjuvant in 
vaccination strategies to favor the induction of CD8
+
 T cell responses. This hypothesis was 
investigated using, as a model, a vaccine candidate against HSV1 infection. Specifically, 
we explored the use of a live-attenuated HSV1 vector expressing Tat (LvTat, see “Material 
and  Methods” section for details) compared to a control HSV1 vector expressing LacZ 
(LvLacZ). To this aim, C57BL/6 mice were immunized intravaginally (i.vag.) with LvTat 
or LvLacZ vectors and the percentage of CD8
+
 T cells specific for an immunodominant 
HSV-derived K
b
-restricted epitope CD8
+
 (SSI) was  measured by dextramer staining at 
days  7, 14, 28 and 120 post immunization (Scheme 7).  
 
 
Scheme 7 
 
 
As shown in Figure 3.19, the percentage of SSI-specific CD8
+
 T cells in blood was 
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and memory phases (day 120 p.i.) in mice immunized with LvTat compared to the control 
group inoculated with LvLacZ. 
 
 
 
 
Figure 3.19. Tat increases the percentage of SSI-specific CD8
+
 T cells. Blood samples were collected at 
days 7, 14, 28 and 120 post-immunization from LvLacZ and LVTat immunized C57/BL6 mice. The 
percentage of SSI-specific CD8
+
 T cells detected by dextramer staining in whole blood are shown. Data are 
presented as mean ± SEM of 5 mice per group. For statistical analysis two-tailed Mann Whitney test was 
used. *P<0.05.  
 
 
Furthermore, the number of SSI-specific CD8
+
 T cells was also evaluated in spleens and 
lymph nodes at day 7 (expansion phase) and at day 120 (memory phase). As shown in 
Figures 3.20 and 3.21, significantly higher numbers of HSV-specific CD8
+
 T cells were 
present in the spleens but not in lymph nodes of mice immunized with LvTat compared to 
mice immunized with LvLacZ.  
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Figure 3.20. Tat increases the number of SSI-specific CD8
+
 T cells in spleens. At days 7 and 120 post-
infection splenocytes were harvested from LVLacZ and LVTat immunized C57/BL6 mice. Total number of 
SSI-specific CD8
+
 T cells was detected by dextramer staining. Data are presented as mean ± SEM of 5 mice 
per group. For statistical analysis two-tailed Mann Whitney test was used. *P<0.05.  
 
 
 
 
Figure 3.21. Tat does not increase the number of SSI-specific CD8
+
 T cells in lymph nodes. At days  7 
and 120 post-infection lymph nodes were harvested from HSV1-LacZ and HSV1-Tat HSV1-infected 
C57/BL6 mice. Percentage of SSI-specific CD8
+
 T cells was detected by dextramer staining. Data are 
presented as mean ± SEM of 5 mice per group. 
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To assess whether Tat affects the phenotype of SSI-specific CD8+ T cells, we evaluated 
the expression of KLRG and CD127, since the expression of these markers define two 
distinct populations of effector CD8
+
 T cells: CD127
-
KLRG
+ 
 short lived effector cells 
(SLECs) which confer immediate protection, but contribute little to the long-lived memory 
repertoire and CD127
+
KLRG1
-
 memory precursor effector cells (MPECs) which have the 
ability to respond to survival signals and develop into long-lived memory cells. 
Thus, we evaluated, at day 7 post-immunization, the percentage of SSI-specific CD8
+ 
MPECs and SLECs in blood, spleens and lymph nodes of C57/BL6 mice immunized with 
LvLacZ or LVTat vectors. Similar percentage of SSI-specific CD8
+
 MPECs and SLECs 
were detected at day 7 in blood, spleens and lymph nodes and no significant differences 
were detected among mice immunized with LvTat and LvLacZ (Figure 3.22 a-c).  
 
 
Figure 3.22. Tat effect on the phenotype of effector SSI-specific CD8
+
 T cells. Blood samples (a), spleen 
(b) and lymph nodes (c) were collected at day 7 post immunization from LvLacZ and LVTat immunized 
C57/BL6 mice. Proportion of MPEC (CD127
+
KLRG1
-
) and SLEC (CD127
-
KLRG
+
) is shown as percentage 
of SSI-specific CD8
+
 T cells. Data are presented as mean ± SEM of 5 mice per group. 
 
Since antigen-experienced T cells can be phenotypically classified into effector memory T 
cells (TEM) and central memory T cells (TCM) by CD62L expression (TEM are CD62L
-
), we 
then evaluated the phenotype of SSI-specific memory CD8
+
 T cells. To this aim, the 
expression of CD62L was investigated on SSI-specific CD8
+
 T cells in blood, spleen, and 
lymph nodes after immunization with LvTat and LvLacZ. As shown in Figure 3.23, the 
analysis of the phenotype of SSI-specific CD8
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revealed a significant lower expression of CD62L in LvTat immunized mice, indicating a 
larger population of HSV1-specific effector memory CD8
+
 T cells. 
 
Figure 3.23. Tat effect on the phenotype of memory SSI-specific CD8
+
 T cells. Blood samples were 
collected at days  14, 28 and 120 post-immunization from LvLacZ and LVTat immunized C57/BL6 mice. 
Proportion of effector memory T cells (CD62L
-
) is shown as percentage of SSI-specific CD8
+
 T cells. Data 
are presented as mean ± SEM of 5 mice per group. For statistical analysis two-tailed Mann Whitney test was 
used. *P<0.05.  
 
 
 
Furthermore, the analysis was performed in spleens and lymph node at day 120 post 
immunization. As show in Figure 3.24, LvTat-immunized mice displayed, compared to 
control mice, a significant lower expression of CD62L
 
in SSI-specific CD8
+
 T cells in 
spleens, while in lymph nodes this difference is less marked but still present. 
 
Thus, these data show that the immunization with LvTat is capable of inducing a 
larger number of HSV1-specific CD8
+
 T cells and increases the number of effector 
memory T cells. Of note, some recent studies indicate that an effector memory 
phenotype is associated to a better protection induced by vaccination [152, 153]. 
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Figure 3.24. Tat effect on the phenotype of memory SSI-specific CD8
+
 T cells. Spleen (a) and lymph 
nodes (b) were collected at day 120 post immunization from LvLacZ and LVTat immunized C57/BL6 mice. 
Proportion of effector memory T cells (CD62L
-
) is shown as percentage of SSI-specific CD8
+
 T cells. Data 
are presented as mean ± SEM of 5 mice per group. For statistical analysis two-tailed Mann Whitney test was 
used. *P<0.05. 
 
3.13 Immunization with an attenuated HSV1 vector expressing Tat favors the control 
of HSV1 infection 
 
We demonstrated that immunization with LvTat increases the number of SSI-specific 
CD8
+
 T cells and favors an effector memory phenotype. We next tried to understand 
whether this Tat-mediated modulation of the pool of HSV-specific T cells may provide 
protection against genital HSV infection. To this aim, mice were challenged intravaginally 
with a lethal dose of wild type HSV at 128 days after immunization and viral titers were 
measured in vaginal lavages at days 1, 2, 3 post-challenge (Scheme 8). 
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Notably, at day 1, 2 and 3 post challenge, mice immunized with LvTat manifested 
significantly less viral titers in the vagina compared  to mice immunized with LvLacZ 
(Figure 3.25) suggesting a better control of HSV1 infection.  
 
These results demonstrate that LvTat immunization could enhance protective 
immunity against HSV infection decreasing viral replication in vagina. 
 
Figure 3.25. Tat decreases viral titers after challenge. Viral titers were measured in vaginal lavages at 
days 1, 2, 3 post-challenge. Data are presented as mean ± SEM of 5 mice per group. For statistical analysis 
two-tailed Mann Whitney test was used. *P<0.05. 
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4. DISCUSSION 
 
We demonstrate here that the HIV-1 Tat protein, which is released by infected cells and 
found extracellularly in HIV-positive individuals [88, 99, 107], favors the activation and 
effector functions of CD8
+
 and CD4
+
 T cells (Figures 3.3, 3.4,3.5 and 3.15). Interestingly, 
behind this functional modulation we observed that Tat increases the expression of T-bet, 
Eomes, Blimp-1, Bcl-6 and Bcl-2 in CD8
+
 T lymphocytes purified from activated PBLs 
(Figures 3.8 and 3.9) and in CD4
+
 T lymphocytes activated alone (Figures 3.10 and 3.11) 
but not in unstimulated  CD8
+
 and CD4
+
 T cells (Figures 3.17). The Tat-mediated increase 
of the expression of T-bet in CD8
+
 and CD4
+
 T cells and of Eomes only in CD8
+
 T cells, 
suggests that Tat may impact the T cell programming of CD8
+
 and CD4
+
 T lymphocytes. 
This effect requires the interaction of Tat with integrins (Figure 3.12) and leads to the 
down-regulation of CD127 and the up-regulation of CD27 (Figure 3.14). Interestingly, the 
effect of Tat on activated CD8
+
 T cells was abolished only when CD8+ T cells were 
activated in the presence of other cells type, suggest the requirement of cell-to-cell contact 
or the release of soluble factors. Other studies are required to clarify this observation. 
It is known that Tat favors IL-2 secretion in CD4
+
 T cells [102]. Here we show for the first 
time that also CD8
+
 T cells activated in the presence of Tat exhibited increased production 
of IL-2 (Figures  3.3 and 3.4). Several mechanisms may account for this effect, as it has 
been reported that Tat favors the activation of TFs required for IL-2 transcription, like NF-
κB [92, 103], NFAT [154] and AP-1 [155]. Moreover, Tat superinduces factors binding to 
the CD28-responsive element (CD28RE) which mediates IL-2 gene activation by CD28 
co-stimulation [92, 103]. 
The results also demonstrate that naïve and memory CD8
+
 T cells activated in vitro in the 
presence of Tat exhibit an increased IFNγ production and cytotoxic activity (Figures 3.5 
and 3.15). The effect was abolished when Tat was added after the stimulation, suggesting 
that Tat favors the expansion and the functionality of effector cells only if present at the 
beginning of the stimulation. It is likely that Tat potentiates the production of cytokines 
and cytolytic molecules through the induction of T-bet, Eomes and Blimp-1 (Figures 3.8 
and 3.9), which control at different levels the transcription of IFNγ, perforins and 
granzymes [45, 145, 156]. The interaction of the RGD domain of Tat with αvβ3 and α5β1 
integrins seems to be necessary, as we observed that the Tat-mediated up-regulation of the 
TFs was abolished by integrins blocking. It is known that Tat mediates the activation of the 
ERK/MAPK and PI3K/Akt pathways through its RGD domain [157, 158], and both ERK 
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and Akt are involved in T-bet induction [159, 160]. Moreover, the ERK pathway also 
favors Eomes and Blimp-1 up-regulation [161, 162].  
Of note, an increased production of effector molecules like IFNγ and granzymes, as well as 
an enhancement of T-bet and Eomes in CD8
+
 T cells, are observed in HIV-infected 
individuals [79, 163-166]. Thus, our in vitro observations suggest that Tat may be 
responsible of, or contribute to all these in vivo effects.  
However, PBLs, CD8
+
 and CD4
+
 T cells activated by anti-CD3/CD28 in the presence of 
Tat did not exhibited an increased proliferation (Figures 3.6 and 3.7). This is consistent 
with literature data showing that T-bet deficiency does not affect secretory capacity, 
proliferation and phenotype of CD8
+
 T cells activated with anti-CD3/CD28, while T-bet-
deficient CD8
+
 T cells fail to acquire effector phenotype and functionality after peptide 
stimulation [167]. Thus, the control of T-bet on T cell functions is strictly dependent on the 
quality of the stimulus. Moreover these results suggest that hyperproliferation of T cells 
observed during immune activation in HIV-infected individuals may not be due directly to 
Tat effects. The lack of proliferation even in the presence of IL-2 up-regulation suggest an 
intriguingly mechanism that needs further elucidation. As discussed below, it is possible 
that the Tat-mediated IL-2 increase is limited to the initial hours after stimulation and then 
repressed by Tat-mediated Blimp-1 and T-bet up-regulation [167] in both activated CD8
+
 
and CD4
+
 T cells, and this would explain  the lack of increased proliferation. 
The role of Tat on T cell survival is highly debated [118, 168-170]. We report that Tat 
enhances the expression of the anti-apoptotic marker Bcl-2 in activated CD8
+
 and CD4
+
 T 
cells. However, the up-regulation of Bcl-2 does not appear to be due to a direct effect of 
Tat on Bcl-2 expression, as instead demonstrated in CD4
+
 T cells [118], since it was 
observed after activation with anti-CD3/CD28 and Tat further increased it. Thus, our 
results indicate that Tat may differently affect Bcl-2 expression in CD4
+
 and CD8
+
 T cells. 
We found that CD8
+
 and CD4
+
 T cells activated in the presence of Tat exhibited increased 
levels of Blimp-1, which favors the development of effector memory T cells [156, 171], a 
phenomenon that we have also observed in vivo by immunization of mice with a 
recombinant HSV1 vector expressing Tat. Intriguingly, we also observed the up-regulation 
of Bcl-6, which is repressed by Blimp-1 [171], suggesting a Tat-mediated mechanism that 
deserves further investigations. Moreover, the presence of Tat favors the expression of 
CD27, a hallmark of incomplete differentiation to effector cells [11, 172, 173], and causes 
CD127 down-regulation not only in unstimulated CD8
+
 T cells, as previously 
demonstrated [121, 174], but also in activated CD8
+
 T lymphocytes. Interestingly, CD127 
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down-regulation is observed in HIV-infected individuals in association with immune 
activation [119, 175], higher levels of T-bet and Eomes and increased granzyme B and 
IFNγ release [79]. 
In conclusion, our results indicate that Tat modulates programming and secretory capacity 
of both CD8
+
 and CD4
+
 T cells, suggesting that it may be involved in the development of 
T lymphocytes with an effector profile as observed during HIV infection [3, 79]. We 
propose a model by which HIV, through the release of Tat, may affect T-bet and Eomes 
expression thus contributing to immune activation and to a profound and long-lasting 
modulation of T cell responses.  
 
Thus, our observations provide new hints on the role that Tat may play in CD8
+
 and 
CD4
+
 T cell dysfunctionalities during HIV infection, suggesting that the induction 
anti-Tat immune responses may be a valuable tool to protect HIV-infected 
individuals from immune dysfunctions.  
 
The modulation of the pathways that lead to optimal generation and maintenance of T cells 
is of considerable importance for the development of both prophylactic and therapeutic 
vaccines able to induce broad, strong, long lasting and protective immune responses. Thus, 
the characterization of molecules able to increase the immunogenicity of a vaccine may be 
a valuable tool for the identification of new strategies for vaccine development. We believe 
that the capacity of Tat to activate T cells, may be beneficial for the development of new 
vaccines in which Tat may play the role of adjuvant. Indeed, our in vitro results 
demonstrate that Tat affects the transcriptional profile of T lymphocytes and increases T 
cell functions. Moreover, it is known that Tat modulates the functionality of CD4
+
 T 
lymphocytes [92, 102, 103, 106, 118, 123] and professional APCs [176] and affects in vivo 
the magnitude and kinetics of antiviral responses [177]. Tat also induces changes in the 
subunit composition of the immune proteasome, which correlate to altered enzymatic 
activities and modulation of CTL epitope generation in virally-infected cells and broadens 
in vivo T cell responses against subdominat epitopes of a co-antigen (otherwise not 
expressed, or only poorly expressed) [123, 142, 178]. 
In this study we have characterized  CD8
+
 T cell responses in an in vivo model of 
immunization with a HSV vector expressing Tat. 
We demonstrate that the presence of Tat within a vector favored the expansion and 
mantainence of epitope-specific CD8
+
 T cells (Figures 3.19 and 3.20). We also observe 
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that Tat favors the development of effector memory T cells (Figures 3.23 and 3.24), which 
have been recently demonstrated to be optimal for protective immunity against certain 
pathogens [152]. Importantly, we show that immunization with a viral vector expressing 
Tat confers protection to mice challenged with a lethal dose of HSV1 (Figure 3.25).  
These observations, in addition to our previous in vivo findings showing that Tat induces 
epitope-speciﬁc T cell responses directed against subdominant and cryptic epitopes of 
heterologous antigens which are not detected in mice vaccinated in the absence of Tat 
[142], suggest that this protein may be used as powerful adiuvant in vaccination strategies. 
 
Taken together these results indicate that Tat modulates CD8
+
 T cellular responses in 
vivo and that these responses are associated with a better protection against a 
reinfection. Thus, the immunomodulatory proprieties of Tat may be exploited for 
vaccination strategies and therapeutic interventions aimed at modulating antigen-
specific immune responses in different types of human diseases. 
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5. MATERIALS AND METHODS 
 
5.1 Human cells and culture conditions 
 
Buffy coats from healthy volunteers, that provided consent, were obtained from the 
University Hospital of Ferrara. Peripheral blood lymphocytes (PBLs) were separated by 
use of Ficoll–Hypaque (Lonza, Basel, Switzerland) density gradient centrifugation 
followed by 90 minutes of adhesion on a plastic support at 37°C to remove monocytes. 
PBLs (3x10
6
) were cultured in 2 ml of RPMI (Gibco, Life Technologies, Carlsbad, CA, 
USA) containing 10% FCS (complete medium) in the absence or presence of the Tat 
protein in 24-well flat bottomed polystyrene plates coated overnight at 4°C with PBS or 
anti-CD3 mAb (0.5 µg/ml; R&D Systems, Minneapolis, MN, USA). Soluble anti-CD28 
mAb (0.1 µg/ml; R&D Systems), Tat and anti-Tat immune sera were added, when 
indicated, after cells seeding.  In the blocking experiments with anti-integrins antibodies 
cells were preincubated on rotation in RPMI + 0.05% BSA containing the competitor 
antibodies at the concentrations of 10 μg/ml for one hour at room temperature.  MoAbs 
raised against the whole α5β1 or αvβ3 integrins were purchased from Merck Millipore 
(Billerica, MA, USA).  
CD4
+
 and CD8
+
 T cells were sorted by MACS magnetic negative selection (Miltenyi 
Biotec, Bergish Gladbach, Germany) according to manufacturer’s instructions (purity > 
95% assessed by FACS).  
PHA-activated blasts were obtained by stimulation of PBLs with 1 µg/ml purified PHA 
(Sigma-Aldrich, St. Louis, MO, USA) for 3 days at 37°C and expanded in complete 
medium supplemented with human rIL-2 (10 U/ml; R&D Systems). 
The 174/T2 cell line (T2) was obtained by fusion of the peptide transporter mutant 174 
LCL with the T cell line CEM. Cells were cultured overnight at 26°C in 1 ml of serum-free 
AIM-V medium (Gibco). Cells were washed, treated with mitomycin C (Sigma-Aldrich), 
and pulsed with 10
-5
 M of the different peptides for 3 hours at 37°C in AIM-V medium. 
For intracellular staining, cells were activated with anti-CD3 and anti-CD28 mAbs. 96-
well flat bottomed polystyrene plates were coated overnight at 4°C with PBS and anti-CD3 
mAb (1.5 µg/ml). Soluble anti-CD28 mAb (1 µg/ml), anti-CD49d (1 µg/ml), and, when 
required, Tat, were added after cells seeding (1x10
6
 cells per well in 0.2 ml of complete 
medium). 
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5.2 Tat protein 
 
HIV-1 Tat (sequence: MEPVDPRLEPWKHPGSQPKT ACTNCYCKKCCFHCQVCFIT 
KALGIS YG RK KRRQRRR PPQGSQTHQVSLSKQ PTSQSRGDPTGPKE) from the 
human T lymphotropic virus type IIIB isolate (BH10 clone) was expressed in Escherichia 
coli and purified by heparin-affinity chromatography and HPLC, as described previously 
[176]. The lyophilized Tat protein was stored at -80°C to prevent oxidation, reconstituted 
in degassed buffer before use, and handled, as described [176]. Endotoxin concentration 
was undetectable (detection threshold: 0.05 EU/µg).  
 
5.3 Reverse transcription (RT) and quantitative real time PCR 
 
DNase-treated total RNA was isolated from cells using Trizol reagent (Life Technologies) 
according to the manufacturer's instructions and used to perform cDNA synthesis (High 
Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Life Technologies). 
cDNA was PCR-amplified with a Chromo4 real-time PCR Detection System using Kapa 
SYBR Green Fast qPCR Kit (Kapabiosystems, Wilmington, MA, USA) according to the 
manufacturer's recommendations with the following cycle conditions: 3 minutes at 95°C, 
then 40 cycles of 15 seconds at 95°C, and 20 seconds at 60°C. Quantitative PCR was 
performed using the pairs of primers (TEMA ricerca, Bologna, Italy) shown in Table 5.1. 
The relative levels for each RNA were calculated by the 2
−ΔΔCT
 method using human 18S 
as housekeeping gene. CT values are the mean of two biological replicates and each assay 
was performed a minimum of two times. 
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Gene Forward 5’-3’ Reverse 5’-3’ 
T-bet GCGCCAGGAAGTTTCATTTG  GGAAAGTAAAGATATGCGTGTTGG 
Eomes TCATTACGAAACAGGGCAGG                 TGCATGTTATTGTCGGCTTTG 
IL-2 AAGAATCCCAAACTCACCAGG  ATTGCTGATTAAGTCCCTGGG 
IFNγ TGACCAGAGCATCCAAAAGAG CGACAGTTCAGCCATCACTTG 
Bcl-2 GATCCAGGATAACGGAGGC GGCATGTTGACTTCACTTGTG 
Bcl-6 CCCTATCCCTGTGAAATCTGTG CTGGCTTTTGTGACGGAAATG 
Blimp-1 ACTGGGTAGAGATGAACGAGAC CCACAGAGTCATATCCGCATC 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Table 5.1. Primers used for qPCR. 
 
5.4 Intracellular staining 
 
PBLs were stimulated with anti-CD3, anti-CD28 and anti-CD49d as described above in the 
presence of Monensin (1 μg per well) and CD107b-FITC (bioscience product). Duration of 
stimulation varied in different assays. PBLs were stimulated for 2 h before adding 
Brefeldin A (BFA; Sigma-Aldrich). After stimulation, PBLs were washed once with PBS 
and incubated with EDTA for 15 minutes at room temperature. Subsequently, surface 
proteins were stained for 20 minutes and cells were washed twice with FACS buffer (PBS, 
1% FCS). The cells were permeabilized using the Cytofix/Cytoperm kit (BD), after which 
they were stained with anti-CD3 APC-Cy7, anti-IFNγ V450 and anti-IL-2 APC (BD). 
Cells were then washed twice and fixed in CellFix (BD). Cells were analyzed with a 
FACScanto II. Electronic compensation was conducted with antibody capture beads (BD) 
stained separately with the individual antibodies used in the test samples. Flow cytometry 
data were analyzed using FlowJo (version 8.8.3; Tree Star, Inc.).  
 
5.5 Bio-Plex assay 
 
Cytokines in cells culture supernatants were measured by Bio-Plex cytokine assay (Bio-
Rad Laboratories, Hercules, CA) according to the manufacturer's recommendations. 
Briefly, 50 µl of cytokine standards or samples (supernatants recovered from treated cells) 
were incubated with 50 µl of anti-cytokine conjugated beads in 96-well filter plates for 30 
min at room temperature under shaking. Plates were then washed by vacuum filtration 
Materials and Methods 
65 
 
three times with 100 µl of Bio-Plex wash buffer, 25 µl of diluted detection antibody was 
added and plates were incubated for 30 min at room temperature under shaking. After 3 
filter washes, 50 µl of streptavidin–phycoerythrin was added, and the plates were 
incubated for 10 min at room temperature under shaking. Finally, plates were washed by 
vacuum filtration three times, beads were suspended in Bio-Plex assay buffer and samples 
were analyzed on a Bio-Rad 96-well plate reader using the Bio-Plex Suspension Array 
System and Bio-Plex Manager software (Bio-Rad). 
 
5.6 MTT assay 
 
MTT test was used to study T cells survival. PBLs were seeded in triplicate in 96-well 
plates at a density of 1x10
5
 in a final volume 100 µl of complete medium and Tat was 
added at the concentration of 0.1 or 1 µg/ml. For stimulation with anti-CD3/CD28, plates 
were pre-coated overnight with 0.3 µg of anti-CD3 mAb/well at 4°C, and 0.2 µg of anti-
CD28 mAb was added at the time of cells seeding. For stimulation with PHA or PMA, 0.2 
µg of PHA or 1 ng of PMA and 125 ng of ionomycin were added at the time of cells 
seeding. For stimulation of LPS, 1µg of LPS was added at the time of cells seeding. Cells 
were cultured for 6 days, and then 25 µl of a 3-(4,5-dimethylthiozol-2-yl)2,5-
diphenyltetrazolium bromide solution (MTT, Sigma-Aldrich) (12 mM) were added. After 2 
hours of incubation, 100 µl of lysing buffer (50% dimethylformamide (DMF) + 20% 
sodium dodecyl sulfate (SDS), pH 4.7) were added to convert the MTT solution into a 
violet colored formazane. After additional 18 hours the solution absorbance, proportional 
to the number of live cells, was measured by spectrophotometer at 570 nm.  
 
5.7 CFSE assay 
 
CD4
+
 and CD8
+
 T cells proliferation was measured using CFSE, a cell division tracking 
dye (Molecular Probes, Eugene, OR). The cells were incubated at 37  C for 10 min and 
then the reaction was stopped by adding 4–5 volumes of cold RPMI 1640 medium 
containing 10% FCS. After washing and re-suspending the cells into the warm RPMI 1640 
medium with 10% FCS, they were then plated in anti-CD3/CD28 Ab coated plates. After 6 
days of incubation, the cells were stained with CD4-PerCP-Cy5.5 and CD8-PE Ab 
(ImmunoTools, Friesoythe, Germany) and acquired for FACS analysis. Unstimulated 
CFSE-labeled cells served as a nondividing control. 
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5.8 Western blotting  
 
Cell extracts, corresponding to 10 μg of total proteins (quantified by BCA protein assay 
kit, Pierce, Waltham, MA, USA), were loaded onto 12% SDS-polyacrylamide gels and 
analyzed by Western Blotting procedure. 
Blots were probed with antibodies specific for T-bet (Millipore, Billerica, MA, USA) at 
1:1000 dilution, Eomes (Millipore) at 1:200 dilution and β-actin (Sigma-Aldrich) at 
1:10000. Immunocomplexes were detected by means of the ECL Western Blot detection 
kit (Amersham Pharmacia, GE Healthcare, Little Chalfont, U.K.).  
 
5.9 Flow cytometry 
 
All stainings were carried out in PBS containing 1% FCS for 30 min at 4°C.  For staining 
of human samples the following antibodies were utilized: CD45RO-FITC, CD25-FITC, 
CD8-PE, CD27-PE, CD8-PE-Dy647 (ImmunoTools); CD127-PerCP-Cy 5.5 (BD 
Pharmingen, San Diego, CA, USA). Data were acquired on a BD FACScan and analyzed 
using BD Cell Quest Pro software.  
For staining of mice samples the following antibodies were utilized: CD8 APC-H7 
(Immunotools); CD127 PE-Cy7, KLRG1 APC, CD62L PE, CD62L FITC (eBioscience); 
CD3 PerCP-Cy5.5 (BD Biosciences). For dextramer staining, cells (1 × 10
6
) were 
incubated for 10 minutes at room temperature with PE labeled HSV1 K
b
-restricted peptides 
SSIEFARL (SSI) dextramer (Immudex) and washed prior staining with surface antigen 
antibodies for 30 minutes at 4°C.  
Data were acquired on a BD FACScan or a BD FACS Canto II and analyzed using BD 
Cell Quest Pro or Diva softwares.  
 
5.10 Generation of CTL cultures 
 
HLA A11-restricted EBV-specific CTL cultures reacting against the EBV-encoded nuclear 
Ag 4 (EBNA4)-derived IVTDFSVIK (IVT, aa 416–424) and HLA A2-restricted EBV-
specific CTL cultures reacting against the EBV-encoded LMP2-derived CLGGLLTMV 
(CLG, aa 426–434) epitope and the LMP1-derived YLQQNWWTL (YLQ, aa 159–167) 
epitope were obtained by stimulation, in the absence or presence of Tat (0.1 µg/ml), of 
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lymphocytes from HLA-A2-positive and HLA-A11-positive EBV-seropositive volunteers 
with peptide-pulsed T2 cells. HLA A2-restricted survivin-specific CTL cultures reacting 
against the survivin tumor antigen ELT (ELTLGEFLKL) were obtained by stimulation, in 
the absence or presence of Tat (0.1 µg/ml), of lymphocytes from HLA-A2-positive healthy 
volunteers with peptide-pulsed T2 cells [179].  
Briefly, PBLs were plated at 3x10
6
 cells per well in 24-well plates in complete medium 
and stimulated with peptide-pulsed T2 cells at a stimulator-responder ratio of 1:20, in the 
absence or presence of Tat. Alternatively, cells were stimulated directly with peptides (10
-5 
M) in the absence or presence of Tat. Cultures were re-stimulated after 7 and 14 days, and 
the medium was supplemented from day 8 with 10 U/ml rIL-2. On days 21, CTL cultures 
were tested for activity using cytotoxicity or Elispot assays. 
Peptides were synthetized by solid phase method and purified by HPLC to >98% purity 
(UF Peptides, University of Ferrara). 
 
5.11 Cytotoxicity assay 
 
The cytotoxic activity was assayed in standard 5-hours 
51
Cr-release assays [148]. Target 
cells (PHA blasts) were labeled with Na2
51
CrO4 (3.5 MBq/10
6
 cells; PerkinElmer, 
Waltham, MA, USA) for 60 minutes at 37°C and, where indicated, pulsed for 45 minutes 
with 10
-6
 M of the different peptides at 37°C. Subsequently, cells were washed 3 times and 
incubated with effector cells. 
51
Cr-release was measured after 5 hours at 37°C through the 
use of a γ-counter. Maximum 51Cr-release was evaluated treating target cells with Triton 
X-100, while spontaneous 
51
Cr-release was evaluated in target cells incubated alone in 
complete medium. Cytotoxicity tests were routinely run at different E:T ratios in triplicate. 
Percentage of specific lysis was calculated as 100 x (cpm sample - cpm medium)/(cpm 
Triton X-100 - cpm medium). Spontaneous release was always < 10%. None of the tested 
peptides affected spontaneous release. 
 
5.12 Elispot assay 
 
CTLs (4 x 10
4
) were seeded in triplicate on microplate 96-well unifilter (Whatman, GE 
Healthcare, Little Chalfont, U.K.) pre-coated with an anti-IFNγ and granzyme B mAb 
(Pierce). CTLs were stimulated with CLG and YLQ EBV-derived CD8 peptides. CTLs 
incubated with medium alone were used as negative control, whereas CTLs stimulated 
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with PHA represented the positive control. Plates were incubated for 24 hours and washed, 
and then a biotinylated anti-IFNγ and granzyme B mAb (1 µg/ml) was added to the wells. 
After 60 min, the plates were washed again and HRP-conjugated streptavidin (Pierce) was 
added at room temperature for 45 minutes. Individual IFNγ and granzyme B producing 
cells were detected using 3-amino-9-ethylcarbazole cromogen kit (Sigma-Aldrich) and 
counted by ELISPOT reader (AELVIS, Hannover, Germany). The number of specific 
IFNγ and granzyme B secreting T cells, expressed as spot-forming units per 106 cells, was 
calculated by subtracting the negative control values. 
 
5.13 Viruses 
 
Mice were immunized using HSV1 attenuated replication-competent vectors expressing 
Tat (LvTat) or LacZ as control gene (LvLacZ). 
The recombinant attenuated replication-competent HSV1LacZ (LvLacZ), where the UL41 
gene is deleted by the insertion of the lacZ gene under the control of the HSV ICP0pr, and 
the recombinant live attenuated LTat vector (LvTat), constructed by means of homologous 
recombination between UL41 sequences of the pB41-tat plasmid and the HSV1-LacZ 
vector, were generated and provided by the laboratory of Dr. Peggy Marconi, Department 
of Life Science and Biotechnology, University of Ferrara. 
The wild-type Herpes Simplex virus type 1 (HSV1), LV strain [180], was used for 
challenge experiments. 
 
5.14 Mice immunization, challenge and samples collection 
 
C57BL/6 female mice (Charles River Laboratories) were pretreated, one week before 
infection, with 2 μg/100 μl of Depo-Provera® (Depo-medroxy-progesterone acetate; 
Pharmacia & Upjohn) subcutaneously in the neck, to bring the mice at the same estrous 
stage and render them more susceptible to HSV1 infection. C57BL/6 mice were inoculated 
intravaginally with 1 x 10
4
 of LvLacZ and LvTat. Before injection, the virus was thawed 
on ice, sonicated for 5 seconds, and stored on ice. Mice were anaesthetized with 5% 
isofluorane to allow scraping of the vagina with a pipe scraper (in order to remove the 
mucus that could trap the virus) and then inoculated with the purified virus (in 10 μl of 
total volume for each mouse) using a pipette-tip.  
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After infection, mice were observed daily to monitor the appearance of local and/or 
systemic clinical signs of infection including death. Mice were sacrificed at different time 
points to analyse anti-HSV1 immune responses in spleen and lymph nodes by dextramer 
staining. Alternatively, blood samples were collected in heparinized tubes from retro-
orbital plexus. Red blood cells were lysed twice using 3 ml of red blood cell lysing buffer 
(Sigma-Aldrich) at different time points to measure HSV-specific cellular responses by 
dextramer staining.  
At sacrifice, mice were anesthetized intraperitoneally with 100 μl of isotonic solution 
containing 1 mg of Zoletil (Virbac) and 200 μg Rompun (Bayer) to collect blood and 
spleens. 
At day 128, mice (n=5 per experimental group) were challenged intravaginally with a 
lethal dose of wild-type HSV1 (strain LV; 1.5 x 10
8
 pfu per mice). Viral stocks were 
titered in vitro, according to standard procedures [181], and stored at -80 °C. Titers of viral 
stocks ranged between 7 x 10
9
 to 2 x 10
11
 plaque forming units (pfu)/ml. After challenge, 
vaginal washes were collected in PBS and store at -20° C to perform virus titrations.  
Mice were observed daily to monitor their health and the appearance of clinical signs. 
Each group was composed of three/five animals. Mice experiments were conducted 
according to European and Institutional guidelines for housing and care of laboratory 
animals and performed under protocols approved by the Italian Ministry for Health. 
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